PHILIPPINE BIDDING DOCUMENTS

SUPPLY AND DELIVERY OF VARIOUS DRUGS AND MEDICINES FOR CHARITY IN-PATIENT AND RESALE – AMPULES/VIALS FOR CY2024 (FRAMEWORK AGREEMENT)

Project Reference No.: BAC1-2023-11-0100A & BAC1-2023-11-0101A

End-User: **Property and Supply Division**

UP – PHILIPPINE GENERAL HOSPITAL
Taft Avenue, Manila

Preface

These Philippine Bidding Documents (PBDs) for the procurement of Goods through Competitive Bidding have been prepared by the Government of the Philippines for use by any branch, constitutional commission or office, agency, department, bureau, office, or instrumentality of the Government of the Philippines, National Government Agencies, including Government-Owned and/or Controlled Corporations, Government Financing Institutions, State Universities and Colleges, and Local Government Unit. The procedures and practices presented in this document have been developed through broad experience, and are for mandatory use in projects that are financed in whole or in part by the Government of the Philippines or any foreign government/foreign or international financing institution in accordance with the provisions of the 2016 revised Implementing Rules and Regulations of Republic Act No. 9184.

The Bidding Documents shall clearly and adequately define, among others: (i) the objectives, scope, and expected outputs and/or results of the proposed contract or Framework Agreement, as the case may be; (ii) the eligibility requirements of Bidders; (iii) the expected contract or Framework Agreement duration, the estimated quantity in the case of procurement of goods, delivery schedule and/or time frame; and (iv) the obligations, duties, and/or functions of the winning bidder.

Care should be taken to check the relevance of the provisions of the PBDs against the requirements of the specific Goods to be procured. If duplication of a subject is inevitable in other sections of the document prepared by the Procuring Entity, care must be exercised to avoid contradictions between clauses dealing with the same matter.

Moreover, each section is prepared with notes intended only as information for the Procuring Entity or the person drafting the Bidding Documents. They shall not be included in the final documents. The following general directions should be observed when using the documents:

a. All the documents listed in the Table of Contents are normally required for the procurement of Goods. However, they should be adapted as necessary to the circumstances of the particular Procurement Project.

b. Specific details, such as the "*name of the Procuring Entity*" and "*address for bid submission*," should be furnished in the Instructions to Bidders, Bid Data Sheet, and Special Conditions of Contract. The final documents should contain neither blank spaces nor options.

c. This Preface and the footnotes or notes in italics included in the Invitation to Bid, Bid Data Sheet, General Conditions of Contract, Special Conditions of Contract, Schedule of Requirements, and Specifications are not part of the text of the final document, although they contain instructions that the Procuring Entity should strictly follow.

d. The cover should be modified as required to identify the Bidding Documents as to the Procurement Project, Project Identification Number, and Procuring Entity, in addition to the date of issue.

e. Modifications for specific Procurement Project details should be provided in the Special Conditions of Contract as amendments to the Conditions of Contract. For easy completion, whenever reference has to be made to specific clauses in the Bid Data Sheet or Special Conditions of Contract, these terms shall be printed in bold typeface on Sections I (Instructions to Bidders) and III (General Conditions of Contract), respectively.

f. For guidelines on the use of Bidding Forms and the procurement of Foreign-Assisted Projects, these will be covered by a separate issuance of the Government Procurement Policy Board.

Table of Contents

Glossary of Acronyms, Terms, and Abbreviations

ABC –Approved Budget for the Contract.

BAC – Bids and Awards Committee.

Bid – A signed offer or proposal to undertake a contract submitted by a bidder in response to and in consonance with the requirements of the bidding documents. Also referred to as *Proposal* and *Tender.* (2016 revised IRR, Section 5[c])

Bidder – Refers to a contractor, manufacturer, supplier, distributor and/or consultant who submits a bid in response to the requirements of the Bidding Documents. (2016 revised IRR, Section 5[d])

Bidding Documents – The documents issued by the Procuring Entity as the bases for bids, furnishing all information necessary for a prospective bidder to prepare a bid for the Goods, Infrastructure Projects, and/or Consulting Services required by the Procuring Entity. (2016 revised IRR, Section 5[e])

BIR – Bureau of Internal Revenue.

BSP – Bangko Sentral ng Pilipinas.

Consulting Services – Refer to services for Infrastructure Projects and other types of projects or activities of the GOP requiring adequate external technical and professional expertise that are beyond the capability and/or capacity of the GOP to undertake such as, but not limited to: (i) advisory and review services; (ii) pre-investment or feasibility studies; (iii) design; (iv) construction supervision; (v) management and related services; and (vi) other technical services or special studies. (2016 revised IRR, Section 5[i])

CDA - Cooperative Development Authority.

Contract – Refers to the agreement entered into between the Procuring Entity and the Supplier or Manufacturer or Distributor or Service Provider for procurement of Goods and Services; Contractor for Procurement of Infrastructure Projects; or Consultant or Consulting Firm for Procurement of Consulting Services; as the case may be, as recorded in the Contract Form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.

CIF – Cost Insurance and Freight.

CIP – Carriage and Insurance Paid.

CPI – Consumer Price Index.

DDP – Refers to the quoted price of the Goods, which means "delivered duty paid."

DTI – Department of Trade and Industry.

EXW – Ex works.

FCA – "Free Carrier" shipping point.

FOB – "Free on Board" shipping point.

Foreign-funded Procurement or Foreign-Assisted Project–Refers to procurement whose funding source is from a foreign government, foreign or international financing institution as specified in the Treaty or International or Executive Agreement. (2016 revised IRR, Section 5[b]).

Framework Agreement – Refers to a written agreement between a procuring entity and a supplier or service provider that identifies the terms and conditions, under which specific purchases, otherwise known as "Call-Offs," are made for the duration of the agreement. It is in the nature of an option contract between the procuring entity and the bidder(s) granting the procuring entity the option to either place an order for any of the goods or services identified in the Framework Agreement List or not buy at all, within a minimum period of one (1) year to a maximum period of three (3) years. (GPPB Resolution No. 27-2019)

GFI – Government Financial Institution.

GOCC –Government-owned and/or –controlled corporation.

Goods – Refer to all items, supplies, materials and general support services, except Consulting Services and Infrastructure Projects, which may be needed in the transaction of public businesses or in the pursuit of any government undertaking, project or activity, whether in the nature of equipment, furniture, stationery, materials for construction, or personal property of any kind, including non-personal or contractual services such as the repair and maintenance of equipment and furniture, as well as trucking, hauling, janitorial, security, and related or analogous services, as well as procurement of materials and supplies provided by the Procuring Entity for such services. The term "related" or "analogous services" shall include, but is not limited to, lease or purchase of office space, media advertisements, health maintenance services, and other services essential to the operation of the Procuring Entity. (2016 revised IRR, Section 5[r])

GOP – Government of the Philippines.

GPPB – Government Procurement Policy Board.

INCOTERMS – International Commercial Terms.

Infrastructure Projects – Include the construction, improvement, rehabilitation, demolition, repair, restoration or maintenance of roads and bridges, railways, airports, seaports, communication facilities, civil works components of information technology projects, irrigation, flood control and drainage, water supply, sanitation, sewerage and solid waste management systems, shore protection, energy/power and electrification facilities, national

buildings, school buildings, hospital buildings, and other related construction projects of the government. Also referred to as *civil works or works*. (2016 revised IRR, Section 5[u])

LGUs – Local Government Units.

NFCC – Net Financial Contracting Capacity.

NGA – National Government Agency.

PhilGEPS - Philippine Government Electronic Procurement System.

Procurement Project – refers to a specific or identified procurement covering goods, infrastructure project or consulting services. A Procurement Project shall be described, detailed, and scheduled in the Project Procurement Management Plan prepared by the agency which shall be consolidated in the procuring entity's Annual Procurement Plan. (GPPB Circular No. 06-2019 dated 17 July 2019)

PSA – Philippine Statistics Authority.

SEC – Securities and Exchange Commission.

SLCC – Single Largest Completed Contract.

Supplier – refers to a citizen, or any corporate body or commercial company duly organized and registered under the laws where it is established, habitually established in business and engaged in the manufacture or sale of the merchandise or performance of the general services covered by his bid. (Item 3.8 of GPPB Resolution No. 13-2019, dated 23 May 2019). Supplier as used in these Bidding Documents may likewise refer to a distributor, manufacturer, contractor, or consultant.

UN – United Nations.

Section I. Invitation to Bid

Notes on the Invitation to Bid

The Invitation to Bid (IB) provides information that enables potential Bidders to decide whether to participate in the procurement at hand. The IB shall be posted in accordance with Section 21.2 of the 2016 revised IRR of RA No. 9184.

Apart from the essential items listed in the Bidding Documents, the IB should also indicate the following:

a. The date of availability of the Bidding Documents, which shall be from the time the IB is first advertised/posted until the deadline for the submission and receipt of bids;

b. The place where the Bidding Documents may be acquired or the website where it may be downloaded;

c. The deadline for the submission and receipt of bids; and

d. Any important bid evaluation criteria (*e.g.*, the application of a margin of preference in bid evaluation).

The IB should be incorporated in the Bidding Documents. The information contained in the IB must conform to the Bidding Documents and in particular to the relevant information in the Bid Data Sheet.

University of the Philippines Manila
The Health Sciences Center
BIDS & AWARDS COMMITTEE 1
BAC 1Office, PGH Compound
Taft Avenue, Manila
Tel. No. 554-8400 local 3014 / 3015

INVITATION TO BID
FOR

Project Reference No.: BAC1-2023-11-0100A & BAC1-2023-11-0101A

Supply and Delivery of Various Drugs and Medicines for Charity In-Patient and Resale- Ampules/Vials for CY2024 (Framework Agreement)

1. The ***University of the Philippines – Philippine General Hospital (UP-PGH)***, invites PhilGEPS registered suppliers to bid in accordance with the the provisions of the Revised IRR of R.A. 9184 on the use of the **Approved Guidelines on the use of a Single Year Framework Agreement (Outright Determination of Lowest Calculated and Responsive Bid) under GPPB Resolution No. 27-2019.**

2. The ***University of the Philippines – Philippine General Hospital (UP-PGH)*** intends to apply the sum of **SIX HUNDRED NINETY NINE MILLION FOUR HUNDRED THREE THOUSAND ONE HUNDRED NINETEEN PESOS & 25/100 (Php699,403,119.25) ONLY,** through the *General Appropriations Act CY 2024***, inclusive of all taxes, such as, but not limited to, value added tax (VAT), income tax, local taxes, and other fiscal levies**, *being the ABC to payments under the contract for each item. Bids received in excess of the total cost per item shall be automatically rejected.*

3. The **University of the Philippines– Philippine General Hospital (UP-PGH)** now invites bids for **the Supply and Delivery of Various Drugs and Medicines for Charity In-Patients and Resale- Ampules/Vials for CY2024 (Framework Agreement)**. Delivery of the Goods is required after issuance of a Call-Off as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-Off is already available for pick-up. Bidders should have completed, ***within two (2) years*** from the date of submission and receipt of bids, a contract similar to the Project. The description of an eligible bidder is contained in the Bidding Documents, particularly, in Section II (Instructions to Bidders).

4. Bidding will be conducted through open competitive bidding procedures using a non-discretionary "*pass/fail*" criterion as specified in the 2016 revised Implementing Rules and Regulations (IRR) of Republic Act (RA) No. 9184.

   Bidding is restricted to Filipino citizens/sole proprietorships, partnerships, or organizations with at least sixty percent (60%) interest or outstanding capital stock belonging to citizens of the Philippines, and to citizens or organizations of a country the

laws or regulations of which grant similar rights or privileges to Filipino citizens, pursuant to RA No. 5183.

5. Prospective Bidders may obtain further information from ***UP-PGH BAC 1 Secretariat*** and inspect the Bidding Documents at the address given below during office hours from ***8:00AM to 4:30PM***.

6. A complete set of Bidding Documents may be acquired by interested Bidders on **10 January 2024** from the given address and website(s) below and upon payment of the applicable fee for the Bidding Documents, pursuant to this Invitation and the latest Guidelines issued by the GPPB, in the amount of ***(to be determined upon issuance of bid documents).*** The Procuring Entity shall allow the bidder to present its proof of payment for the fees in person, or through electronic means.

7. The UP-PGH will hold a **Pre-Bid Conference** on **19 January 2024**, **9:30AM** onwards at the -BAC1 Office Conference Room, PGH Compound, Taft Avenue, Manila. Which shall be open to prospective bidders and/or through video conferencing or webcasting via [ZOOM], which shall be open to prospective bidders.

8. Bids must be duly received by the **UP-PGH BAC 1 Secretariat** through *manual submission at the office address indicated below*, on or before **9:00AM, 02 February 2024**. Late bids shall not be accepted.

9. All Bids must be accompanied by a bid security in any of the acceptable forms and in the amount stated in ITB Clause 14.

10. **Bid opening** shall be on **9:30AM**, **02 February 2024** at the given address below. Bids will be opened in the presence of the bidders' representatives who choose to attend the activity.

11. The UP-PGH reserves the right to reject any and all bids, declare a failure of bidding, or not award the contract at any time prior to contract award in accordance with Sections 35.6 and 41 of the 2016 revised IRR of RA No. 9184, without thereby incurring any liability to the affected bidder or bidders.

12. For further information, please refer to:

    Bids and Awards Committee I Secretariat
    UP-Philippine General Hospital
    PGH Compound, Taft Avenue, Manila
    Telephone No.: 8-554-8400 local 3014/3015
    e-Mail Address: bac1pgh.upm@up.edu.ph

    You may visit the following websites:
    https://bidsandawards.upm.edu.ph/

    For downloading of Bidding Documents: *[www.philgeps.gov.ph]*

_____

Dean CHARLOTTE M. CHIONG, MD, PhD
Chairperson, Bids and Awards Committee (BAC) 1

Section II. Instructions to Bidders

Notes on the Instructions to Bidders

This Section on the Instruction to Bidders (ITB) provides the information necessary for bidders to prepare responsive bids, in accordance with the requirements of the Procuring Entity. It also provides information on bid submission, eligibility check, opening and evaluation of bids, post-qualification, and on the award of contract.

1. Scope of Bid

The Procuring Entity, **UP-PGH** wishes to receive Bids for the **Supply and Delivery of Various Drugs and Medicines for Charity In-Patients and Resale-Ampules/Vials for CY2024** under a Framework Agreement, with identification number **BAC1-2023-11-0100A and BAC1-2023-11-0101A.**

The Procurement Project (referred to herein as "Project") is composed of **one hundred eighty-seven (187) line items**, the details of which are described in Section VII (Technical Specifications).

2. Funding Information

2.1. The GOP through the source of funding as indicated below for ***General Appropriations Act CY 2024*** in the amount of **SIX HUNDRED NINETY NINE MILLION FOUR HUNDRED THREE THOUSAND ONE HUNDRED NINETEEN PESOS & 25/100 (Php699,403,119.25) ONLY.**

2.2. The source of funding is:

a. NGA, the National Expenditure Program

3. Bidding Requirements

The Bidding for the Project shall be governed by all the provisions of RA No. 9184 and its 2016 revised IRR, including its Generic Procurement Manuals and associated policies, rules and regulations as the primary source thereof, while the herein clauses shall serve as the secondary source thereof.

Any amendments made to the IRR and other GPPB issuances shall be applicable only to the ongoing posting, advertisement, or **ITB** by the BAC through the issuance of a supplemental or bid bulletin.

The Bidder, by the act of submitting its Bid, shall be deemed to have verified and accepted the general requirements of this Project, including other factors that may affect the cost, duration and execution or implementation of the contract, project, or work and examine all instructions, forms, terms, and project requirements in the Bidding Documents.

4. Corrupt, Fraudulent, Collusive, and Coercive Practices

The Procuring Entity, as well as the Bidders and Suppliers, shall observe the highest standard of ethics during the procurement and execution of the contract. They or through an agent shall not engage in corrupt, fraudulent, collusive, coercive, and obstructive practices defined under Annex "I" of the 2016 revised IRR of RA No. 9184 or other integrity violations in competing for the Project.

5. Eligible Bidders

5.1. Only Bids of Bidders found to be legally, technically, and financially capable will be evaluated.

5.2. Foreign ownership exceeding those allowed under the rules may participate pursuant to:

i. When a Treaty or International or Executive Agreement as provided in Section 4 of the RA No. 9184 and its 2016 revised IRR allow foreign bidders to participate;

ii. Citizens, corporations, or associations of a country, included in the list issued by the GPPB, the laws or regulations of which grant reciprocal rights or privileges to citizens, corporations, or associations of the Philippines;

iii. When the Goods sought to be procured are not available from local suppliers; or

iv. When there is a need to prevent situations that defeat competition or restrain trade.

5.3. Pursuant to Section 23.4.1.3 of the 2016 revised IRR of RA No.9184, the Bidder shall have an SLCC that is at **least one (1) contract similar to the Project** the value of which, adjusted to current prices using the PSA's CPI, must be at least equivalent to:

a. For the procurement of Non-expendable Supplies and Services: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least fifty percent (50%) of the ABC.

b. **For the procurement of Expendable Supplies: The Bidder must have completed a single contract that is similar to this Project, equivalent to at least twenty-five percent (25%) of the ABC**.

c. For procurement where the Procuring Entity has determined, after the conduct of market research, that imposition of either (a) or (b) will likely result to failure of bidding or monopoly that will defeat the purpose of public bidding: the Bidder should comply with the following requirements: [*Select either failure or monopoly of bidding based on market research conducted*]

i. Completed at least two (2) similar contracts, the aggregate amount of which should be equivalent to at least *fifty percent (50%) in the case of non-expendable supplies and services or twenty-five percent (25%) in the case of expendable supplies*] of the ABC for this Project; and

ii. The largest of these similar contracts must be equivalent to at least half of the percentage of the ABC as required above.

5.4. The Bidders shall comply with the eligibility criteria under Section 23.4.1 of the 2016 IRR of RA No. 9184.

6. Origin of Goods

There is no restriction on the origin of goods other than those prohibited by a decision of the UN Security Council taken under Chapter VII of the Charter of the UN, subject to Domestic Preference requirements under **ITB** Clause 18.

7. Subcontracts

7.1. The Bidder may subcontract portions of the Project to the extent allowed by the Procuring Entity as stated herein, but in no case more than twenty percent (20%) of the Project.

The Procuring Entity has prescribed that:

a. **Subcontracting is not allowed.**

8. Pre-Bid Conference

The Procuring Entity will hold a pre-bid conference for this Project on the specified date and time and either at its physical address at the **UP-Philippine General Hospital, Bids and Awards Committee I PGH Compound, Taft Avenue, Manila,** and/or through **ZOOM** as indicated in paragraph 6 of the **IB.**

9. Clarification and Amendment of Bidding Documents

Prospective bidders may request for clarification on and/or interpretation of any part of the Bidding Documents. Such requests must be in writing and received by the Procuring Entity, either at its given address or through electronic mail indicated in the **IB**, at least ten (10) calendar days before the deadline set for the submission and receipt of Bids.

10. Documents comprising the Bid: Eligibility and Technical Components

10.1. The first envelope shall contain the eligibility and technical documents of the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.

10.2. The Bidder's SLCC as indicated in **ITB** Clause5.3 should have been completed within prior to the deadline for the submission and receipt of bids.

10.3. If the eligibility requirements or statements, the bids, and all other documents for submission to the BAC are in foreign language other than English, it must be accompanied by a translation in English, which shall be authenticated by the appropriate Philippine foreign service establishment, post, or the

equivalent office having jurisdiction over the foreign bidder's affairs in the Philippines. Similar to the required authentication above, for Contracting Parties to the Apostille Convention, only the translated documents shall be authenticated through an apostille pursuant to GPPB Resolution No. 13-2019 dated 23 May 2019. The English translation shall govern, for purposes of interpretation of the bid.

11. Documents comprising the Bid: Financial Component

11.1. The second bid envelope shall contain the financial documents for the Bid as specified in **Section VIII (Checklist of Technical and Financial Documents)**.

11.2. If the Bidder claims preference as a Domestic Bidder or Domestic Entity, a certification issued by DTI shall be provided by the Bidder in accordance with Section 43.1.3 of the 2016 revised IRR of RA No. 9184.

11.3. Any bid exceeding the ABC indicated in paragraph 1 of the **IB** shall not be accepted.

11.4. For Foreign-funded Procurement, a ceiling may be applied to bid prices provided the conditions are met under Section 31.2 of the 2016 revised IRR of RA No. 9184.

11.5. Financial proposals for single or multi-year Framework Agreement shall be submitted before the deadline of submission of bids as prescribed in the **IB**. For multi-year Framework Agreement, evaluation of the financial proposal during this stage is for purposes of determining eligibility and whether or not such financial proposal is within the ABC.

12. Bid Prices

12.1. Prices indicated on the Price Schedule shall be entered separately in the following manner:

a. For Goods offered from within the Procuring Entity's country:

i. The price of the Goods quoted EXW (ex-works, ex-factory, ex-warehouse, ex-showroom, or off-the-shelf, as applicable);

ii. The cost of all customs duties and sales and other taxes already paid or payable;

iii. The cost of transportation, insurance, and other costs incidental to delivery of the Goods to their final destination; and

iv. The price of other (incidental) services, if any, listed in e.

b. For Goods offered from abroad:

i. Unless otherwise stated in the **BDS**, the price of the Goods shall be quoted delivered duty paid (DDP) with the place of destination in the Philippines as specified in the **BDS**. In quoting the price, the Bidder shall be free to use transportation through carriers registered in any eligible country. Similarly, the Bidder may obtain insurance services from any eligible source country.

ii. The price of other (incidental) services, if any, as listed in **Section VII (Technical Specifications).**

12.2. For Framework Agreement, the following should also apply in addition to Clause 12.1:

a. For a single year Framework Agreement, the prices quoted by the Bidder shall be fixed during the Bidder's performance of the contract and not subject to variation or escalation on any account. Price schedules required under Clause 12.1 shall be submitted with the bidding documents.

b. For a multi-year Framework Agreement, the prices quoted by the Bidder during submission of eligibility documents shall be the ceiling and the price quoted during mini-competition must not exceed the initial price offer. The price quoted during call for mini-competition shall be fixed during the Bidder's performance of that Call-off and not subject to variation or escalation on any account. Price schedules required under Clause 12.1 shall be submitted with the bidding documents.

13. Bid and Payment Currencies

13.1. For Goods that the Bidder will supply from outside the Philippines, the bid prices may be quoted in the local currency or tradeable currency accepted by the BSP at the discretion of the Bidder. However, for purposes of bid evaluation, Bids denominated in foreign currencies, shall be converted to Philippine currency based on the exchange rate as published in the BSP reference rate bulletin on the day of the bid opening.

13.2. Payment of the contract price shall be made in:
a. **Philippine Pesos**.

14. Bid Security

14.1. The Bidder shall submit a Bid Securing Declaration[1] or any form of Bid Security in the amount indicated in the **BDS**, which shall be not less than the percentage of the ABC in accordance with the schedule in the **BDS**.

14.2. The Bid and bid security shall be valid until ***One Hundred Twenty (120) calendar days from the date of opening of bids.*** Any Bid not accompanied by an acceptable bid security shall be rejected by the Procuring Entity as non-responsive.

14.3. In the case of Framework Agreement, other than the grounds for forfeiture under the 2016 revised IRR, the ***bid security may also be forfeited if the***

[1] In the case of Framework Agreement, the undertaking shall refer to entering into contract with the Procuring Entity and furnishing of the performance security or the performance securing declaration within ten (10) calendar days from receipt of Notice to Execute Framework Agreement.

successful bidder fails to sign the Framework Agreement or fails to furnish the performance security or performance securing declaration. Without prejudice on its forfeiture, bid securities shall be returned only after the posting of performance security or performance securing declaration, as the case may be, by the winning Bidder or compliant Bidders and the signing of the Framework Agreement.

15. Sealing and Marking of Bids

Each Bidder shall submit ***two (2) copies – one (1) original and one (1) copy of the first and second components of its Bid***.

The Procuring Entity may request additional hard copies and/or electronic copies of the Bid. However, failure of the Bidders to comply with the said request shall not be a ground for disqualification.

If the Procuring Entity allows the submission of bids through online submission or any other electronic means, the Bidder shall submit an electronic copy of its Bid, which must be digitally signed. An electronic copy that cannot be opened or is corrupted shall be considered non-responsive and, thus, automatically disqualified.

16. Deadline for Submission of Bids

16.1. The Bidders shall submit on the specified date and time and either at its physical address or through online submission as indicated in paragraph 7 of the **IB.**

16.2. For multi-year Framework Agreement, the submission of bids shall be for the initial evaluation of their technical and financial eligibility. Thereafter, those declared eligible during the said initial eligibility evaluation and entered into a Framework Agreement with the Procuring Entity shall submit anew their best financial offer at the address and on or before the date and time indicated in the Call for each mini-competition.

17. Opening and Preliminary Examination of Bids

17.1. The BAC shall open the Bids in public at the time, on the date, and at the place specified in paragraph 9 of the **IB**. The Bidders' representatives who are present shall sign a register evidencing their attendance. In case videoconferencing, webcasting or other similar technologies will be used, attendance of participants shall likewise be recorded by the BAC Secretariat.

In case the Bids cannot be opened as scheduled due to justifiable reasons, the rescheduling requirements under Section 29 of the 2016 revised IRR of RA No. 9184 shall prevail.

17.2. The preliminary examination of bids shall be governed by Section 30 of the 2016 revised IRR of RA No. 9184.

18. Domestic Preference

18.1. The Procuring Entity will grant a margin of preference for the purpose of comparison of Bids in accordance with Section 43.1.2 of the 2016 revised IRR of RA No. 9184.

18.2. For multi-year Framework Agreement, determination of margin of preference shall be conducted every call for Mini-Competition.

19. Detailed Evaluation and Comparison of Bids

19.1. The Procuring BAC shall immediately conduct a detailed evaluation of all Bids rated "*passed*," using non-discretionary pass/fail criteria. The BAC shall consider the conditions in the evaluation of Bids under Section 32.2 of the 2016 revised IRR of RA No. 9184.

a. ***In the case of single-year Framework Agreement, the Lowest Calculated Bid shall be determined outright after the detailed evaluation***.

b. For multi-year Framework Agreement, the determination of the eligibility and the compliance of bidders with the technical and financial aspects of the projects shall be initially made by the BAC, in accordance with Item 7.4.2 of the Guidelines on the Use of Framework Agreement.

19.2. If the Project allows partial bids, bidders may submit a proposal on any of the lots or items, and evaluation will be undertaken on a per lot or item basis, as the case maybe. In this case, the Bid Security as required by **ITB** Clause 15 shall be submitted for each lot or item separately.

19.3. The descriptions of the lots or items shall be indicated in **Section VII (Technical Specifications)**, although the ABCs of these lots or items are indicated in the **BDS** for purposes of the NFCC computation pursuant to Section 23.4.2.6 of the 2016 revised IRR of RA No. 9184. The NFCC must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder.

19.4. The Project shall be awarded as follows:

Option 1 – ***One Project having several items that shall be awarded with several contracts as evaluated per item basis.***

19.5. Except for bidders submitting a committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation, all Bids must include the NFCC computation pursuant to Section 23.4.1.4 of the 2016 revised IRR of RA No. 9184, which must be sufficient for the total of the ABCs for all the lots or items participated in by the prospective Bidder. For bidders submitting the committed Line of Credit, it must be at least equal to ten percent (10%) of the ABCs for all the lots or items participated in by the prospective Bidder.

20. Post-Qualification

20.1. For multi-year Framework Agreement, all bidders initially determined to be eligible and financially compliant shall be subject to initial post-qualification. The BAC shall then recommend the execution of a Framework Agreement among all eligible, technically and financially compliant bidders and the Procuring Entity and shall be issued by HoPE, a Notice to Execute Framework Agreement. The determination of the Lowest Calculated Bid (LCB) shall not be performed by the BAC until a Mini-Competition is conducted among the bidders who executed a Framework Agreement. When a Call for Mini-Competition is made, the BAC shall allow the bidders to submit their best financial proposals on such pre-scheduled date, time and place to determine the bidder with the LCB.

20.2. Within a non-extendible period of five (5) calendar days from receipt by the Bidder of the notice from the BAC that it submitted the Lowest Calculated Bid, or in the case of multi-year Framework Agreement, that it is one of the eligible bidders who have submitted bids that are found to be technically and financially compliant,}the Bidder shall submit its latest income and business tax returns filed and paid through the BIR Electronic Filing and Payment System (eFPS) and other appropriate licenses and permits required by law and stated in the **BDS**. For every mini-competition in Framework Agreement, the LCB shall likewise submit the required documents for final Post Qualification.}

21. Signing of the Contract

21.1. The documents required in Section 37.2 of the 2016 revised IRR of RA No. 9184 shall form part of the Contract. Additional Contract documents are indicated in the **BDS**.

21.2. At the same time as the Procuring Entity notifies the successful Bidder that its bid has been accepted, the Procuring Entity shall send the Framework Agreement Form to the Bidder, which contract has been provided in the Bidding Documents, incorporating therein all agreements between the parties.

21.3. Within ten (10) calendar days from receipt of the Notice to Execute Framework Agreement with the Procuring Entity, the successful Bidder or its duly authorized representative shall formally enter into a Framework Agreement with the procuring entity for an amount of One Peso to be paid to the procuring entity as a consideration for the option granted by the procuring entity to procure the items in the Framework Agreement List when the need arises.

21.4. The Procuring Entity shall enter into a Framework Agreement with the successful Bidder within the same ten (10) calendar day period provided that all the documentary requirements are complied with.

21.5. The following documents shall form part of the Framework Agreement:

a. Framework Agreement Form;

b. Bidding Documents;
c. Call-offs;
d. Winning bidder's bid, including the Technical and Financial Proposals, and all other documents/statements submitted (*e.g.*, bidder's response to request for clarifications on the bid), including corrections to the bid, if any, resulting from the Procuring Entity's bid evaluation;
e. Performance Security or Performance Securing Declaration, as the case may be;
f. Notice to Execute Framework Agreement; and
g. Other contract documents that may be required by existing laws and/or specified in the **BDS**.

Section III. Bid Data Sheet

Notes on the Bid Data Sheet

The Bid Data Sheet (BDS) consists of provisions that supplement, amend, or specify in detail, information, or requirements included in the ITB found in Section II, which are specific to each procurement.

This Section is intended to assist the Procuring Entity in providing the specific information in relation to corresponding clauses in the ITB and has to be prepared for each specific procurement.

The Procuring Entity should specify in the BDS information and requirements specific to the circumstances of the Procuring Entity, the processing of the procurement, and the bid evaluation criteria that will apply to the Bids. In preparing the BDS, the following aspects should be checked:

a. Information that specifies and complements provisions of the ITB must be incorporated.

b. Amendments and/or supplements, if any, to provisions of the ITB as necessitated by the circumstances of the specific procurement, must also be incorporated.

Bid Data Sheet

<table>
<tr><th>ITB Clause</th><th></th></tr>
<tr><td>5.3</td><td>For this purpose, contracts similar to the Project shall be:

a. Supply and Delivery of Drugs and Medicines

b. completed within two (2) years prior to the deadline for the submission and receipt of bids.</td></tr>
<tr><td>7.1</td><td>Subcontracting is not allowed</td></tr>
<tr><td>12</td><td>The price of the Goods shall be quoted DDP University of the Philippines – Philippine General Hospital or the applicable International Commercial Terms (INCOTERMS) for this Project.</td></tr>
<tr><td>14.1</td><td>The bid security shall be in the form of a Bid Securing Declaration, or any of the following forms and amounts:

a) The amount of not less than the amount equivalent to two percent (2%) of ABC, if bid security is in cash, cashier’s/manager’s check, bank draft/guarantee or irrevocable letter of credit; or

b) The amount of not less than the amount equivalent to five percent (5%) of ABC, if bid security is in Surety Bond.</td></tr>
<tr><td>19.3</td><td>The NFCC computation, must be sufficient for the contract to be awarded to the Bidder:

<table>
<tr><th rowspan="2">ITEM NO.</th><th rowspan="2">ITEM DESCRIPTION (AGENCY’s REQUIREMENTS)</th><th rowspan="2">MAXIMUM QTY.</th><th rowspan="2">UOM</th><th colspan="2">ABC (Php)</th></tr>
<tr><th>ESTIMATED COST PER ITEM</th><th>TOTAL</th></tr>
<tr><td>1</td><td>Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)</td><td>680</td><td>pc</td><td>1,500.00</td><td>1,020,000.00</td></tr>
<tr><td>2</td><td>Aciclovir 25mg/mL, 10mL vial (IV infusion)</td><td>6,250</td><td>pc</td><td>219.49</td><td>1,371,812.50</td></tr>
<tr><td>3</td><td>Albumin Human 20%, 50mL bottle (IV, IV infusion)</td><td>2,373</td><td>pc</td><td>2,387.00</td><td>5,664,351.00</td></tr>
<tr><td>4</td><td>Adenosine 3 mg/mL, 2 mL vial (IV)</td><td>1,398</td><td>pc</td><td>286.89</td><td>401,072.22</td></tr>
<tr><td>5</td><td>Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)</td><td>14,447</td><td>pc</td><td>74.00</td><td>1,069,078.00</td></tr>
<tr><td>6</td><td>Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)</td><td>19,345</td><td>pc</td><td>97.88</td><td>1,893,488.60</td></tr>
</table>
</td></tr>
</table>

7	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	742	pc	38.00	28,196.00
8	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	6,704	pc	495.00	3,318,480.00
9	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	820	pc	3,300.00	2,706,000.00
10	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	820	pc	10,972.00	8,997,040.00
11	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	32,200	pc	230.00	7,406,000.00
12	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	10,970	pc	245.00	2,687,650.00
13	Ampicillin sodium 250mg vial (IM, IV)	13,550	pc	35.00	474,250.00
14	Ampicillin sodium 500mg vial (IM, IV)	15,395	pc	55.00	846,725.00
15	Asparaginase lyophilized powder, 10,000 IU vial (IV)	2	pc	1,700.00	3,400.00
16	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	8,748	pc	327.00	2,860,596.00
17	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	12,700	pc	115.00	1,460,500.00
18	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	5,550	pc	605.00	3,357,750.00
19	Aztreonam 1g powder for injection (IV, IV Infusion)	1,280	pc	1,290.00	1,651,200.00
20	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	243	pc	15,776.53	3,833,696.79
21	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	2	pc	12,178.00	24,356.00

22	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	10	pc	2,300.00	23,000.00
23	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	7,985	pc	565.00	4,511,525.00
24	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	5,680	pc	327.00	1,857,360.00
25	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	2,660	pc	689.00	1,832,740.00
26	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	1,670	pc	180.00	300,600.00
27	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	36,160	pc	119.00	4,303,040.00
28	Carbachol Intraocular Solution: 0.01%, 1.5 mL vial	600	pc	750.00	450,000.00
29	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	3,735	pc	1,320.00	4,930,200.00
30	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	17	pc	500.00	8,500.00
31	Cefazolin sodium 1gm vial (IM, IV)	29,580	pc	280.00	8,282,400.00
32	Cefepime Hydrochloride 1gm vial (IM, IV)	2,739	pc	350.00	958,650.00
33	Cefepime Hydrochloride 2gms vial (IM, IV)	1,790	pc	398.45	713,225.50
34	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	2,890	pc	698.00	2,017,220.00
35	Cefoxitin sodium 1gm vial (IM, IV)	26,705	pc	935.00	24,969,175.00
36	Ceftazidime pentahydrate 1gm vial (IM, IV)	44,943	pc	200.00	8,988,600.00
37	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	60,480	pc	365.00	22,075,200.00
38	Cefuroxime sodium 750mg vial (IM, IV)	12,613	pc	88.00	1,109,944.00
39	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	8,040	pc	350.00	2,814,000.00
40	Cisplatin 1mg/mL, 50mL vial (IV)	12	pc	450.00	5,400.00
41	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	6,120	pc	198.00	1,211,760.00
42	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	30,000	pc	370.00	11,100,000.00

43	Clonidine hydrocloride 150mcg/mL, 1mL ampule (IV)	3	pc	110.00	330.00
44	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	5,040	pc	2,244.00	11,309,760.00
45	Cytarabine 100 mg/mL solution for injection, 1 mL	12	pc	129.46	1,553.52
46	Cytarabine 100 mg/mL solution for injection, 5 mL	12	pc	355.36	4,264.32
47	Dantrolene Sodium 20 mg (with mannitol 3g)/vial (for reconstitution with 60 mL sterile water for injection) (IV) (With Compassionate Special Permit)	8	pc	18,099.00	144,792.00
48	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	1,620	pc	183.32	296,978.40
49	Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV)	25,495	pc	33.43	852,297.85
50	Dexamethasone sodium phoshate 5mg/mL, 1mL ampule (IM, IV)	35,450	pc	79.78	2,828,201.00
51	Dexmedetomidine 200mcg/2mL (100mcg/mL) single-dose glass vial	842	pc	2,105.30	1,772,662.60
52	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	1,010	pc	138.48	139,864.80
53	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	1,107	pc	200.00	221,400.00
54	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	11,495	pc	98.00	1,126,510.00
55	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	5,051	pc	238.00	1,202,138.00
56	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	2,845	pc	147.45	419,495.25
57	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	12	pc	510.00	6,120.00
58	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	35,393	pc	550.00	19,466,150.00
59	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	21,337	pc	500.00	10,668,500.00

60	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	5,300	pc	88.84	470,852.00
61	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	74,760	pc	32.00	2,392,320.00
62	Epoetin alfa (recombinant human erythropoetin) 10,000 IU/mL, pre-filled syringe (IV, SC)	632	pc	1,498.00	946,736.00
63	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	8,577	pc	530.00	4,545,810.00
64	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	485	pc	312.50	151,562.50
65	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	75	pc	407.67	30,575.25
66	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	3,418	pc	1,278.98	4,371,553.64
67	Ertapenem sodium 1gm powder vial (IM/IV)	4,700	pc	2,144.00	10,076,800.00
68	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	2,118	pc	487.00	1,031,466.00
69	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	3,970	pc	497.00	1,973,090.00
70	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	49,605	pc	58.00	2,877,090.00
71	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC)	2,560	pc	2,578.00	6,599,680.00
72	Fluconazole 2mg/mL, 100mL vial (IV infusion)	9,192	pc	500.00	4,596,000.00
73	Flumazenil 100 micrograms/mL, 5 mL ampul (slow IV, IV infusion)	266	pc	829.50	220,647.00
74	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	124	pc	78.72	9,761.28
75	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul (IV)	600	pc	575.00	345,000.00

76	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	6	pc	74.80	448.80
77	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	214	pc	1,447.04	309,666.56
78	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	84,820	pc	15.00	1,272,300.00
79	Ganciclovir sodium 500 mg vial (IV infusion)	15	pc	1,828.47	27,427.05
80	Gemcitabine Hydrochloride 1gm vial (IV infusion)	5	pc	1,550.00	7,750.00
81	Gemcitabine Hydrochloride 200mg vial (IV infusion)	5	pc	450.00	2,250.00
82	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	11,280	pc	29.45	332,196.00
83	Glucose (dextrose) 50%, 50mL vial (IV)	38,638	pc	78.00	3,013,764.00
84	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	9,165	pc	436.80	4,003,272.00
85	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	2	pc	15,767.24	31,534.48
86	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	2	pc	4,613.06	9,226.12
87	Haloperidol 5 mg/mL, 1 mL ampul (IM)	1,820	pc	731.00	1,330,420.00
88	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	6,344	pc	288.00	1,827,072.00
89	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	4,610	pc	500.00	2,305,000.00
90	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	35	pc	32,062.83	1,122,199.05
91	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	778	pc	54.00	42,012.00
92	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	28,060	pc	150.00	4,209,000.00
93	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder	10,960	pc	370.00	4,055,200.00

	vial (IV)					
94	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	11,620	pc	57.00	662,340.00
95	Ifosfamide powder, 2gms vial (IV infusion)	3	pc	2,025.00	6,075.00
96	Insulin Glargine 100 IU/mL, 10 mL Vial	15	pc	929.46	13,941.90
97	Insulin, regular(recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	2,151	pc	580.00	1,247,580.00
98	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	1,662	pc	580.00	963,960.00
99	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	1,984	pc	398.00	789,632.00
100	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	2,334	pc	544.01	1,269,719.34
101	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	3,299	pc	220.00	725,780.00
102	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	499	pc	216.00	107,784.00
103	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	307	pc	1,729.00	530,803.00
104	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	61,400	pc	45.00	2,763,000.00
105	Leuproreline (as acetate) powder, 3.75mg single dose with syringe (IM, SC)	41	pc	4,160.00	170,560.00
106	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	8,665	pc	1,725.00	14,947,125.00
107	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	9,529	pc	935.00	8,909,615.00
108	Lidocaine Hydrochloride 2% (20 mg/mL), 2 mL ampul/vial (IM/IV)	15,250	pc	56.00	854,000.00
109	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	53,223	pc	35.00	1,862,805.00
110	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM,	2,725	pc	50.00	136,250.00

	IV)					
111	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	4,750	pc	36.00	171,000.00
112	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	164	pc	2,669.94	437,870.16
113	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	11,476	pc	50.00	573,800.00
114	Meropenem trihydrate 1g powder vial (IV)	37,590	pc	650.00	24,433,500.00
115	Meropenem trihydrate 500mg powder vial (IV)	26,520	pc	500.00	13,260,000.00
116	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	1,405	pc	145.00	203,725.00
117	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	685	pc	200.00	137,000.00
118	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	25	pc	5,000.00	125,000.00
119	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	168	pc	89.98	15,116.64
120	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	185	pc	320.00	59,200.00
121	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	1,570	pc	4,099.31	6,435,916.70
122	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	21,773	pc	14.73	320,716.29
123	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	18,375	pc	79.86	1,467,427.50
124	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	18,670	pc	102.00	1,904,340.00
125	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	5,080	pc	104.89	532,841.20
126	Milrinone 10mg/ml, 10ml	1,045	pc	1,689.10	1,765,109.50

			ampule (IV)				
		127	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	6,375	pc	78.45	500,118.75
		128	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	3,235	pc	189.88	614,261.80
		129	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	1,345	pc	413.00	555,485.00
		130	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	19,735	pc	118.00	2,328,730.00
		131	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	1,330	pc	95.00	126,350.00
		132	Nicardipine Hydrochloride 1mg/mL, 10mL ampule (IV)	39,653	pc	385.00	15,266,405.00
		133	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	3,360	pc	175.00	588,000.00
		134	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	65,555	pc	450.00	29,499,750.00
		135	Norepinephrine bitartrate 2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injection	20,640	pc	1,650.00	34,056,000.00
		136	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	3,890	pc	600.00	2,334,000.00
		137	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	81,570	pc	240.00	19,576,800.00
		138	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	13,565	pc	212.78	2,886,360.70
		139	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	13,625	pc	360.00	4,905,000.00
		140	Oxacillin sodium 500mg vial (IM, IV)	28,925	pc	90.00	2,603,250.00
		141	Oxaliplatin 50mg vial powder (IV Infusion)	3	pc	1,160.00	3,480.00
		142	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	29,780	pc	295.00	8,785,100.00
		143	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	318,508	pc	12.00	3,822,096.00
		144	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	8,360	pc	248.88	2,080,636.80

145	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	9,508	pc	238.00	2,262,904.00
146	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	748	pc	150.00	112,200.00
147	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	8,200	pc	18.50	151,700.00
148	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	2,815	pc	28.50	80,227.50
149	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	1,805	pc	492.00	888,060.00
150	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	1,981	pc	554.40	1,098,266.40
151	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	1,630	pc	670.00	1,092,100.00
152	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	11,628	pc	45.89	533,608.92
153	Piperacillin + Tazobactam (as sodium salt) 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)	26,895	pc	298.00	8,014,710.00
154	Piperacillin + Tazobactam (as sodium salt) 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)	46,445	pc	450.00	20,900,250.00
155	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	26,614	pc	3,992.00	106,243,088.00
156	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	11,770	pc	53.00	623,810.00
157	Propofol 10mg/mL, 20mL ampule/vial (IV)	29,730	pc	445.00	13,229,850.00
158	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	1,326	pc	640.00	848,640.00

		159	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	5,963	pc	32.00	190,816.00
		160	Remdesivir 100mg vial lyophilized powder for injection for IV Infusion or 100mg/20ml solution for IV infusion (With Compassionate Special Permit)	140	pc	969.11	135,675.40
		161	Remifentanil 1mg lyophilized powder vial (IV Infusion) (With PDEA Permit)	2,000	pc	1,649.00	3,298,000.00
		162	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	5,334	pc	212.39	1,132,888.26
		163	Ropivacaine Hydrochloride 10mg/mL, 10mL ampule (IV)	2,640	pc	396.46	1,046,654.40
		164	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	2,006	pc	249.79	501,078.74
		165	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	24,646	pc	147.44	3,633,806.24
		166	Sodium Chloride 2.5mEq/mL, 20mL vial	12,651	pc	65.00	822,315.00
		167	Somatostatin 250mcg ampule/vial (IV, IV infusion)	20	pc	754.95	15,099.00
		168	Somatostatin 3mg ampule/vial (IV, IV infusion)	330	pc	4,758.04	1,570,153.20
		169	Streptokinase powder, 1,500,000 IU vial (IV infusion)	35	pc	4,500.00	157,500.00
		170	Streptomycin sulfate 1 g vial (IM)	8	pc	28.00	224.00
		171	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	3,150	pc	5,540.89	17,453,803.50
		172	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	1,344	pc	698.00	938,112.00
		173	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	849	pc	98.88	83,949.12
		174	Tinzaparin (as sodium) 10,000 anti-Xa IU/mL, 0.45	1	pc	711.57	711.57

	mL pre-filled syringe (SC)				
175	Tocilizumab 400mg/ 20ml vial concentrate solution for IV Infusion	5	pc	25,480.00	127,400.00
176	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	23,108	pc	34.80	804,158.40
177	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	3,823	pc	60.00	229,380.00
178	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	65,740	pc	50.00	3,287,000.00
179	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	60	pc	2,405.00	144,300.00
180	Vancomycin Hydrochloride 500mg vial (IV)	16,573	pc	995.00	16,490,135.00
181	Vasopressin 20 IU/mL (IM, IV)	1,783	pc	1,564.50	2,789,503.50
182	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	401	pc	127.94	51,303.94
183	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	3	pc	1,070.00	3,210.00
184	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	60	pc	395.88	23,752.80
185	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	180	pc	400.00	72,000.00
186	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	1,030	pc	200.00	206,000.00
187	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	264	pc	4,699.00	1,240,536.00
TOTAL APPROVED BUDGET FOR THE CONTRACT					**699,403,119.25**

Terms and Conditions:

1. Indicate the **brand and packing of the item/s** offered

2. The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids.** Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).

3. Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).

3.1 Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor.

Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by

them shall be honored by the principal in case of termination of distributorship agreement.

3.2 Valid Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).

- **The name of the respective distributor should appear on the submitted CPR of the drug.**

Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.

3.3 Certificate of Analysis (COA) for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.

3.4 A notarized certificate that it is the innovator drug (if applicable).

3.5 Certificate of Good Manufacturing Process (CGMP).

3.6 Valid License to Operate (LTO).

3.7 A notarized certificate that the offered brand has not been subject to product complaint/product recall for the past three (3) years.

3.8 Certificate of Acceptance from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (*for new item/brand offered only).*

3.9 A notarized certificate that there are sufficient stocks for the offered item/s for one (1) year.

4 All the deliveries conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling and packaging requirements.**

4.1. For all tablets and capsules

4.1.1 All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.

4.1.2 Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.

4.1.3 Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.

4.1.4 Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.

4.1.5 Inner label must be the same as the outer label.

4.1.6 A complete drug literature/product insert must accompany the product.

5. The following must be complied with specific for **cytotoxic injectable drugs.**

For Inhalation Anaesthetics

5.1. 1. Submit certification from the bidder that inhalation bottle must be with

	safety sealed cap, airtight and capable to dispense directly from bottle the possibility of ambient air coming into contact with agent to prevent contamination and spillage 5.1.2. Submit certification from the bidder that product container or anesthetic agent is shatterproof and transparent for visual check of content. Container material must ensure stability of the agent to prevent degradation, must not be easy to break. 5.1.3. Winning bidder for Sevoflurane shall provide at least thirtyfive (35) vaporizers on loan and in good working conditions until the validity of the contract. 5.2. For cytotoxic Injectable Drugs 5.2.1. For cytotoxic injectable drugs, winning bidders are required to *provide Material Safety Data Sheet (MSDS) and to submit Drug Profile* to the Pharmacy Department per company under the first Purchase Order. 5.2.2. Winning bidders for cytotoxic injectable drugs are required to **provide at least three (3) spill kits** per company under the first Purchase Order. 5.2.3. For Paclitaxel, a special IV set bmust be provided per unit of the drug. 6. The brand offered on all antibiotics must have stability that is equivalent to that of the innovator product or better. 7. **New brands offered** shall be subject to further evaluation and shall require the following: 7.1. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals 7.2. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD). 8. **For the supply and delivery of awarded drugs and medicines.** **8.1.** Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up. 8.2. Delivery schedule (whichever is applicable): 8.1.1. 8.2.1. within seven (7) calendar days; 8.1.2. as may be called for; 8.1.3. staggered delivery within three (3) months * 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months *Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital* 8.3. Deliveries should not be less than eighteen (18) months from the time of delivery. Deliveries expiring within twelve (12) months should be guaranteed for replacement if not consumed within six (6) months. A credit memo shall be submiited or effect replacement of fresher stocks within five (5) working days upon receipt of Notice to Supplier (NTS) for pull-out. 8.4. Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items 8.5. Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued. 8.6. Stocks delivered are subject to random sampling for testing as to quality and conformity to label. Testing fee at supplier's expense. 8.7. Stocks with lot #/batch different from the submitted Certificate of Analysis

	(COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense. 8.8. All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier. 8.9. It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).** Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly. 9. Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA9184. 10. Compliance with RA 9184 and other applicable laws.
20.2	**Within a non-extendible period of five (5) days from receipt of the Notice of LCB/Post-Qualification from the BAC, the Bidder shall submit the following:** a) Valid PhilGEPS Registration Certificate (Platinum Membership) (all pages); b) Latest Audited Financial Statement stamped "received by the BIR or its duly accredited and authorized institutions. c) Latest Income and Business Tax Returns filed and paid through the BIR Electronic Filing and Payment System (eFPS); *(only tax returns filed and taxes paid through the BIR Electronic Filing and Payment System (eFPS) shall be accepted)* d) Mayor's or Business permit issued by the Local Government Unit having territorial jurisdiction of your principal place of business, or the equivalent document for Exclusive Economic Zones or Areas; e) Tax clearance per E.O. No. 398; s.2005, as finally reviewed and approved by the Bureau of Internal Revenue (BIR); f) Other appropriate licenses and permits required by law and stated in the Bidding Documents. *In case of Joint Venture, all parties shall submit the same documentation as stated above.*
21.2	Note: Attachments to the List of all ongoing government and private contracts including those awarded but not yet started, similar or not similar to the contract to be bid – (a) Notice of Award, (b) Purchase Order/Contract, (c) Notice to Proceed.

Section IV. General Conditions of Contract

Notes on the General Conditions of Contract

The General Conditions of Contract (GCC) in this Section, read in conjunction with the Special Conditions of Contract in Section V and other documents listed therein, should be a complete document expressing all the rights and obligations of the parties.

Matters governing performance of the Supplier, payments under the contract, or matters affecting the risks, rights, and obligations of the parties under the contract are included in the GCC and Special Conditions of Contract.

Any complementary information, which may be needed, shall be introduced only through the Special Conditions of Contract.

1. Scope of Contract

This Contract shall include all such items, although not specifically mentioned, that can be reasonably inferred as being required for its completion as if such items were expressly mentioned herein. All the provisions of RA No. 9184 and its 2016 revised IRR, including the Generic Procurement Manual, and associated issuances, constitute the primary source for the terms and conditions of the Contract, and thus, applicable in contract implementation. Herein clauses shall serve as the secondary source for the terms and conditions of the Contract.

This is without prejudice to Sections 74.1 and 74.2 of the 2016 revised IRR of RA No. 9184 allowing the GPPB to amend the IRR, which shall be applied to all procurement activities, the advertisement, posting, or invitation of which were issued after the effectivity of the said amendment.

Additional requirements for the completion of this Contract shall be provided in the **Special Conditions of Contract** (**SCC).**

2. Advance Payment and Terms of Payment

2.1. Advance payment of the contract amount is provided under Annex "D" of the revised 2016 IRR of RA No. 9184.

2.2. The Procuring Entity is allowed to determine the terms of payment on the partial or staggered delivery of the Goods procured, provided such partial payment shall correspond to the value of the goods delivered and accepted in accordance with prevailing accounting and auditing rules and regulations. The terms of payment are indicated in the **SCC**.

2.3. For a single-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier in its bid.

2.4. For multi-year Framework Agreement, prices charged by the Supplier for Goods delivered and/or services performed under a Call-Off shall not vary from the prices quoted by the Supplier during conduct of Mini-Competition.

3. Performance Security

Within ten (10) calendar days from receipt of the Notice of Award by the Bidder from the Procuring Entity but in no case later than prior to the signing of the Contract by both parties, the successful Bidder shall furnish the performance security in any of the forms prescribed in Section 39 of the 2016 revised IRR of RA No. 9184. *In the case o*f Framework Agreement, the Bidder may opt to furnish the performance security or a Performance Securing Declaration as defined under the Guidelines on the Use of Framework Agreement.

4. Inspection and Tests

The Procuring Entity or its representative shall have the right to inspect and/or to test the Goods to confirm their conformity to the Project or Framework Agreement specifications at no extra cost to the Procuring Entity in accordance with the Generic Procurement Manual. In addition to tests in the **SCC**, **Section IV (Technical Specifications)** shall specify what inspections and/or tests the Procuring Entity requires, and where they are to be conducted. The Procuring Entity shall notify the Supplier in writing, in a timely manner, of the identity of any representatives retained for these purposes.

All reasonable facilities and assistance for the inspection and testing of Goods, including access to drawings and production data, shall be provided by the Supplier to the authorized inspectors at no charge to the Procuring Entity.

5. Warranty

6.1. In order to assure that manufacturing defects shall be corrected by the Supplier, a warranty shall be required from the Supplier as provided under Section 62.1 of the 2016 revised IRR of RA No. 9184.

6.2. The Procuring Entity shall promptly notify the Supplier in writing of any claims arising under this warranty. Upon receipt of such notice, the Supplier shall, repair or replace the defective Goods or parts thereof without cost to the Procuring Entity, pursuant to the Generic Procurement Manual.

6. Liability of the Supplier

The Supplier's liability under this Contract shall be as provided by the laws of the Republic of the Philippines.

If the Supplier is a joint venture, all partners to the joint venture shall be jointly and severally liable to the Procuring Entity.

Section V. Special Conditions of Contract

Notes on the Special Conditions of Contract

Similar to the BDS, the clauses in this Section are intended to assist the Procuring Entity in providing contract-specific information in relation to corresponding clauses in the GCC found in Section IV.

The Special Conditions of Contract (SCC) complement the GCC, specifying contractual requirements linked to the special circumstances of the Procuring Entity, the Procuring Entity's country, the sector, and the Goods purchased. In preparing this Section, the following aspects should be checked:

a. Information that complements provisions of the GCC must be incorporated.

b. Amendments and/or supplements to provisions of the GCC as necessitated by the circumstances of the specific purchase, must also be incorporated.

However, no special condition which defeats or negates the general intent and purpose of the provisions of the GCC should be incorporated herein.

Special Conditions of Contract

GCC Clause	
1	**Delivery and Documents –** For purposes of the Contract, "EXW," "FOB," "FCA," "CIF," "CIP," "DDP" and other trade terms used to describe the obligations of the parties shall have the meanings assigned to them by the current edition of INCOTERMS published by the International Chamber of Commerce, Paris. The Delivery terms of this Contract shall be as follows: *[For Goods supplied from abroad, state:]* "The delivery terms applicable to the Contract are DDP delivered [*indicate place of destination*]. In accordance with INCOTERMS." "The delivery terms applicable to this Contract are delivered to the ***University of the Philippines Manila – Philippine General Hospital***. Risk and title will pass from the Supplier to the Procuring Entity upon receipt and final acceptance of the Goods at their final destination." Delivery of the Goods shall be made by the Supplier in accordance with the terms specified in **Section VI (Schedule of Requirements).** For purposes of this Clause the Procuring Entity's Representative at the Project Site is **Maria Bernadette P. Idjao, MMPA, Chief Administrative Officer – Property and Supply Division** and **Emelita O. Lavilla, RND, MHA, Chief, Dietary Department** **Incidental Services –** The Supplier is required to provide all of the following services, including additional services, if any, specified in Section VI. Schedule of Requirements: a. performance or supervision of on-site assembly and/or start-up of the supplied Goods; b. furnishing of tools required for assembly and/or maintenance of the supplied Goods; c. furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied Goods; d. training of the Procuring Entity's personnel, at the Supplier's plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the supplied Goods. The Contract price for the Goods shall include the prices charged by the Supplier for incidental services and shall not exceed the prevailing rates charged to other parties by the Supplier for similar services.
	Spare Parts – The Supplier is required to provide all of the following materials, notifications, and information pertaining to spare parts manufactured or distributed by the

	Supplier:
	a. such spare parts as the Procuring Entity may elect to purchase from the Supplier, provided that this election shall not relieve the Supplier of any warranty obligations under this Contract; and b. in the event of termination of production of the spare parts: i. advance notification to the Procuring Entity of the pending termination, in sufficient time to permit the Procuring Entity to procure needed requirements; and ii. following such termination, furnishing at no cost to the Procuring Entity, the blueprints, drawings, and specifications of the spare parts, if requested. The spare parts and other components required are listed in **Section VI (Schedule of Requirements)** and the cost thereof are included in the contract price. The Supplier shall carry sufficient inventories to assure ex-stock supply of consumable spare parts or components for the Goods for a period of **[S*ee attached Terms and Conditions*]**. Spare parts or components shall be supplied as promptly as possible, but in any case, within **[*See attached Terms and Conditions*]** months of placing the order.
	Packaging – The Supplier shall provide such packaging of the Goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in this Contract. The packaging shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packaging case size and weights shall take into consideration, where appropriate, the remoteness of the Goods' final destination and the absence of heavy handling facilities at all points in transit.
	The outer packaging must be clearly marked on at least four (4) sides as follows: Name of the Procuring Entity Name of the Supplier Contract Description Final Destination Gross weight Any special lifting instructions Any special handling instructions Any relevant HAZCHEM classifications A packaging list identifying the contents and quantities of the package is to be

	placed on an accessible point of the outer packaging if practical. If not practical the packaging list is to be placed inside the outer packaging but outside the secondary packaging.
	Transportation – Where the Supplier is required under Contract to deliver the Goods CIF, CIP, or DDP, transport of the Goods to the port of destination or such other named place of destination in the Philippines, as shall be specified in this Contract, shall be arranged and paid for by the Supplier, and the cost thereof shall be included in the Contract Price. Where the Supplier is required under this Contract to transport the Goods to a specified place of destination within the Philippines, defined as the Project Site, transport to such place of destination in the Philippines, including insurance and storage, as shall be specified in this Contract, shall be arranged by the Supplier, and related costs shall be included in the contract price. Where the Supplier is required under Contract to deliver the Goods CIF, CIP or DDP, Goods are to be transported on carriers of Philippine registry. In the event that no carrier of Philippine registry is available, Goods may be shipped by a carrier which is not of Philippine registry provided that the Supplier obtains and presents to the Procuring Entity certification to this effect from the nearest Philippine consulate to the port of dispatch. In the event that carriers of Philippine registry are available, but their schedule delays the Supplier in its performance of this Contract the period from when the Goods were first ready for shipment and the actual date of shipment the period of delay will be considered force majeure. The Procuring Entity accepts no liability for the damage of Goods during transit other than those prescribed by INCOTERMS for DDP deliveries. In the case of Goods supplied from within the Philippines or supplied by domestic Suppliers risk and title will not be deemed to have passed to the Procuring Entity until their receipt and final acceptance at the final destination. **Intellectual Property Rights –** The Supplier shall indemnify the Procuring Entity against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the Goods or any part thereof.
	Regular and Recurring Services – [*In case of contracts for regular and recurring services*, state:] "The contract for regular and recurring services shall be subject to a renewal whereby the performance evaluation of the service provider shall be conducted in accordance with Section VII. Technical specifications."
2.2	Upon execution of the Framework Agreement, the UP-PGH shall pay Php1.00 to the supplier as a consideration for the option granted to procure the items in the

	Framework Agreement list when the need arises. Progress Payment shall be made after acceptance and completion for each call-off complete with the required documentary requirements.
4	**Inspection and Tests –** The inspections and tests that will be conducted shall be in accordance with Section VII. Technical Specifications. • The winning supplier shall submit the Certificate of Product Registration (CPR) for every delivery. **Return of Defective Items and Replacement** All items that failed the inspection shall not be accepted and must be returned immediately. Replacement must be made within the next working day.
5.1	**Warranty Retention:** Three (3) months after acceptance by the Procuring Entity of the delivered Goods or after the Goods are distributed, whichever is earlier. Consistent with GPPB Resolution No. 30-2017, the obligations of the warranty shall be covered by either retention money in an amount equivalent to one percent (1%) of each payment, or special bank guarantee equivalent to one percent (1%) of the total contract price. The said amounts shall only be released after the lapse of the warranty period.

Section VI. Schedule of Requirements

Framework Agreement List

Limited to repeatedly required goods and services that are identified to be necessary and desirable, but, by its nature, use or characteristic, the quantity and/ or exact time of need cannot be accurately pre-determined and are not advisable to be carried in stock.

Prepared by the End-User, attached to the APP and submitted to the BAC for the approval of the HOPE.

ITEM NO.	ITEM/SERVICE TYPE AND NATURE OF EACH ITEM/SERVICE	COST PER ITEM or SERVICE	MAXIMUM QTY.	UOM	TOTAL COST PER ITEM
1	Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)	1,500.00	680	pc	1,020,000.00
2	Aciclovir 25mg/mL, 10mL vial (IV infusion)	219.49	6,250	pc	1,371,812.50
3	Albumin Human 20%, 50mL bottle (IV, IV infusion)	2,387.00	2,373	pc	5,664,351.00
4	Adenosine 3 mg/mL, 2 mL vial (IV)	286.89	1,398	pc	401,072.22
5	Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)	74.00	14,447	pc	1,069,078.00
6	Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)	97.88	19,345	pc	1,893,488.60
7	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	38.00	742	pc	28,196.00
8	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	495.00	6,704	pc	3,318,480.00
9	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	3,300.00	820	pc	2,706,000.00
10	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	10,972.00	820	pc	8,997,040.00
11	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	230.00	32,200	pc	7,406,000.00
12	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	245.00	10,970	pc	2,687,650.00
13	Ampicillin sodium 250mg vial (IM, IV)	35.00	13,550	pc	474,250.00
14	Ampicillin sodium 500mg vial (IM, IV)	55.00	15,395	pc	846,725.00
15	Asparaginase lyophilized powder, 10,000 IU vial (IV)	1,700.00	2	pc	3,400.00
16	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	327.00	8,748	pc	2,860,596.00
17	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	115.00	12,700	pc	1,460,500.00
18	Azithromycin 500 mg powder, vial (IV	605.00	5,550	pc	3,357,750.00

	infusion) (as base*/as dihydrate)				
19	Aztreonam 1g powder for injection (IV, IV Infusion)	1,290.00	1,280	pc	1,651,200.00
20	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	15,776.53	243	pc	3,833,696.79
21	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	12,178.00	2	pc	24,356.00
22	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	2,300.00	10	pc	23,000.00
23	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	565.00	7,985	pc	4,511,525.00
24	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	327.00	5,680	pc	1,857,360.00
25	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	689.00	2,660	pc	1,832,740.00
26	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	180.00	1,670	pc	300,600.00
27	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	119.00	36,160	pc	4,303,040.00
28	Carbachol Intraocular Solution: 0.01%, 1.5 mL vial	750.00	600	pc	450,000.00
29	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	1,320.00	3,735	pc	4,930,200.00
30	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	500.00	17	pc	8,500.00
31	Cefazolin sodium 1gm vial (IM, IV)	280.00	29,580	pc	8,282,400.00
32	Cefepime Hydrochloride 1gm vial (IM, IV)	350.00	2,739	pc	958,650.00
33	Cefepime Hydrochloride 2gms vial (IM, IV)	398.45	1,790	pc	713,225.50
34	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	698.00	2,890	pc	2,017,220.00
35	Cefoxitin sodium 1gm vial (IM, IV)	935.00	26,705	pc	24,969,175.00
36	Ceftazidime pentahydrate 1gm vial (IM, IV)	200.00	44,943	pc	8,988,600.00
37	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	365.00	60,480	pc	22,075,200.00
38	Cefuroxime sodium 750mg vial (IM, IV)	88.00	12,613	pc	1,109,944.00
39	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	350.00	8,040	pc	2,814,000.00
40	Cisplatin 1mg/mL, 50mL vial (IV)	450.00	12	pc	5,400.00
41	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	198.00	6,120	pc	1,211,760.00
42	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	370.00	30,000	pc	11,100,000.00
43	Clonidine hydrocloride 150mcg/mL, 1mL ampule (IV)	110.00	3	pc	330.00
44	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	2,244.00	5,040	pc	11,309,760.00
45	Cytarabine 100 mg/mL solution for injection, 1 mL	129.46	12	pc	1,553.52
46	Cytarabine 100 mg/mL solution for injection, 5 mL	355.36	12	pc	4,264.32

47	Dantrolene Sodium 20 mg (with mannitol 3g)/vial (for reconstitution with 60 mL sterile water for injection) (IV) (With Compassionate Special Permit)	18,099.00	8	pc	144,792.00
48	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	183.32	1,620	pc	296,978.40
49	Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV)	33.43	25,495	pc	852,297.85
50	Dexamethasone sodium phoshate 5mg/mL, 1mL ampule (IM, IV)	79.78	35,450	pc	2,828,201.00
51	Dexmedetomidine 200mcg/2mL (100mcg/mL) single-dose glass vial	2,105.30	842	pc	1,772,662.60
52	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	138.48	1,010	pc	139,864.80
53	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	200.00	1,107	pc	221,400.00
54	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	98.00	11,495	pc	1,126,510.00
55	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	238.00	5,051	pc	1,202,138.00
56	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	147.45	2,845	pc	419,495.25
57	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	510.00	12	pc	6,120.00
58	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	550.00	35,393	pc	19,466,150.00
59	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	500.00	21,337	pc	10,668,500.00
60	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	88.84	5,300	pc	470,852.00
61	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	32.00	74,760	pc	2,392,320.00
62	Epoetin alfa (recombinant human erythropoetin) 10,000 IU/mL, pre-filled syringe (IV, SC)	1,498.00	632	pc	946,736.00
63	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	530.00	8,577	pc	4,545,810.00
64	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	312.50	485	pc	151,562.50
65	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	407.67	75	pc	30,575.25
66	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	1,278.98	3,418	pc	4,371,553.64
67	Ertapenem sodium 1gm powder vial (IM/IV)	2,144.00	4,700	pc	10,076,800.00
68	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	487.00	2,118	pc	1,031,466.00
69	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	497.00	3,970	pc	1,973,090.00

70	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	58.00	49,605	pc	2,877,090.00
71	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC)	2,578.00	2,560	pc	6,599,680.00
72	Fluconazole 2mg/mL, 100mL vial (IV infusion)	500.00	9,192	pc	4,596,000.00
73	Flumazenil 100 micrograms/mL, 5 mL ampul (slow IV, IV infusion)	829.50	266	pc	220,647.00
74	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	78.72	124	pc	9,761.28
75	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul (IV)	575.00	600	pc	345,000.00
76	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	74.80	6	pc	448.80
77	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	1,447.04	214	pc	309,666.56
78	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	15.00	84,820	pc	1,272,300.00
79	Ganciclovir sodium 500 mg vial (IV infusion)	1,828.47	15	pc	27,427.05
80	Gemcitabine Hydrochloride 1gm vial (IV infusion)	1,550.00	5	pc	7,750.00
81	Gemcitabine Hydrochloride 200mg vial (IV infusion)	450.00	5	pc	2,250.00
82	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	29.45	11,280	pc	332,196.00
83	Glucose (dextrose) 50%, 50mL vial (IV)	78.00	38,638	pc	3,013,764.00
84	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	436.80	9,165	pc	4,003,272.00
85	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	15,767.24	2	pc	31,534.48
86	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	4,613.06	2	pc	9,226.12
87	Haloperidol 5 mg/mL, 1 mL ampul (IM)	731.00	1,820	pc	1,330,420.00
88	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	288.00	6,344	pc	1,827,072.00
89	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	500.00	4,610	pc	2,305,000.00
90	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	32,062.83	35	pc	1,122,199.05
91	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	54.00	778	pc	42,012.00
92	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	150.00	28,060	pc	4,209,000.00
93	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	370.00	10,960	pc	4,055,200.00
94	Hyoscine-n-butylbromide 20mg/mL,	57.00	11,620	pc	662,340.00

	1mL ampule (IM, IV, SC)				
95	Ifosfamide powder, 2gms vial (IV infusion)	2,025.00	3	pc	6,075.00
96	Insulin Glargine 100 IU/mL, 10 mL Vial	929.46	15	pc	13,941.90
97	Insulin, regular(recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	580.00	2,151	pc	1,247,580.00
98	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	580.00	1,662	pc	963,960.00
99	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	398.00	1,984	pc	789,632.00
100	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	544.01	2,334	pc	1,269,719.34
101	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	220.00	3,299	pc	725,780.00
102	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	216.00	499	pc	107,784.00
103	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	1,729.00	307	pc	530,803.00
104	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	45.00	61,400	pc	2,763,000.00
105	Leuproreline (as acetate) powder, 3.75mg single dose with syringe (IM, SC)	4,160.00	41	pc	170,560.00
106	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	1,725.00	8,665	pc	14,947,125.00
107	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	935.00	9,529	pc	8,909,615.00
108	Lidocaine Hydrochloride 2% (20 mg/mL), 2 mL ampul/vial (IM/IV)	56.00	15,250	pc	854,000.00
109	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	35.00	53,223	pc	1,862,805.00
110	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	50.00	2,725	pc	136,250.00
111	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	36.00	4,750	pc	171,000.00
112	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	2,669.94	164	pc	437,870.16
113	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	50.00	11,476	pc	573,800.00
114	Meropenem trihydrate 1g powder vial (IV)	650.00	37,590	pc	24,433,500.00
115	Meropenem trihydrate 500mg powder vial (IV)	500.00	26,520	pc	13,260,000.00
116	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	145.00	1,405	pc	203,725.00
117	Methotrexate 25 mg/mL, 2 mL	200.00	685	pc	137,000.00

	ampul/vial (IM, IV, Intrathecal) (as base)				
118	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	5,000.00	25	pc	125,000.00
119	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	89.98	168	pc	15,116.64
120	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	320.00	185	pc	59,200.00
121	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	4,099.31	1,570	pc	6,435,916.70
122	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	14.73	21,773	pc	320,716.29
123	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	79.86	18,375	pc	1,467,427.50
124	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	102.00	18,670	pc	1,904,340.00
125	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	104.89	5,080	pc	532,841.20
126	Milrinone 10mg/ml, 10ml ampule (IV)	1,689.10	1,045	pc	1,765,109.50
127	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	78.45	6,375	pc	500,118.75
128	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	189.88	3,235	pc	614,261.80
129	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	413.00	1,345	pc	555,485.00
130	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	118.00	19,735	pc	2,328,730.00
131	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	95.00	1,330	pc	126,350.00
132	Nicardipine Hydrochloride 1mg/mL, 10mL ampule (IV)	385.00	39,653	pc	15,266,405.00
133	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	175.00	3,360	pc	588,000.00
134	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	450.00	65,555	pc	29,499,750.00
135	Norepinephrine bitartrate 2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injection	1,650.00	20,640	pc	34,056,000.00
136	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	600.00	3,890	pc	2,334,000.00
137	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	240.00	81,570	pc	19,576,800.00
138	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	212.78	13,565	pc	2,886,360.70

139	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	360.00	13,625	pc	4,905,000.00
140	Oxacillin sodium 500mg vial (IM, IV)	90.00	28,925	pc	2,603,250.00
141	Oxaliplatin 50mg vial powder (IV Infusion)	1,160.00	3	pc	3,480.00
142	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	295.00	29,780	pc	8,785,100.00
143	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	12.00	318,508	pc	3,822,096.00
144	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	248.88	8,360	pc	2,080,636.80
145	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	238.00	9,508	pc	2,262,904.00
146	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	150.00	748	pc	112,200.00
147	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	18.50	8,200	pc	151,700.00
148	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	28.50	2,815	pc	80,227.50
149	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	492.00	1,805	pc	888,060.00
150	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	554.40	1,981	pc	1,098,266.40
151	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	670.00	1,630	pc	1,092,100.00
152	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	45.89	11,628	pc	533,608.92
153	Piperacillin + Tazobactam (as sodium salt) 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)	298.00	26,895	pc	8,014,710.00
154	Piperacillin + Tazobactam (as sodium salt) 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)	450.00	46,445	pc	20,900,250.00
155	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	3,992.00	26,614	pc	106,243,088.00
156	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	53.00	11,770	pc	623,810.00
157	Propofol 10mg/mL, 20mL ampule/vial (IV)	445.00	29,730	pc	13,229,850.00
158	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	640.00	1,326	pc	848,640.00
159	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	32.00	5,963	pc	190,816.00
160	Remdesivir 100mg vial lyophilized powder for injection for IV Infusion or 100mg/20ml solution for IV	969.11	140	pc	135,675.40

	infusion (With Compassionate Special Permit)				
161	Remifentanil 1mg lyophilized powder vial (IV Infusion) (With PDEA Permit)	1,649.00	2,000	pc	3,298,000.00
162	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	212.39	5,334	pc	1,132,888.26
163	Ropivacaine Hydrochloride 10mg/mL, 10mL ampule (IV)	396.46	2,640	pc	1,046,654.40
164	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	249.79	2,006	pc	501,078.74
165	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	147.44	24,646	pc	3,633,806.24
166	Sodium Chloride 2.5mEq/mL, 20mL vial	65.00	12,651	pc	822,315.00
167	Somatostatin 250mcg ampule/vial (IV, IV infusion)	754.95	20	pc	15,099.00
168	Somatostatin 3mg ampule/vial (IV, IV infusion)	4,758.04	330	pc	1,570,153.20
169	Streptokinase powder, 1,500,000 IU vial (IV infusion)	4,500.00	35	pc	157,500.00
170	Streptomycin sulfate 1 g vial (IM)	28.00	8	pc	224.00
171	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	5,540.89	3,150	pc	17,453,803.50
172	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	698.00	1,344	pc	938,112.00
173	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	98.88	849	pc	83,949.12
174	Tinzaparin (as sodium) 10,000 anti-Xa IU/mL, 0.45 mL pre-filled syringe (SC)	711.57	1	pc	711.57
175	Tocilizumab 400mg/ 20ml vial concentrate solution for IV Infusion	25,480.00	5	pc	127,400.00
176	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	34.80	23,108	pc	804,158.40
177	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	60.00	3,823	pc	229,380.00
178	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	50.00	65,740	pc	3,287,000.00
179	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	2,405.00	60	pc	144,300.00
180	Vancomycin Hydrochloride 500mg vial (IV)	995.00	16,573	pc	16,490,135.00
181	Vasopressin 20 IU/mL (IM, IV)	1,564.50	1,783	pc	2,789,503.50
182	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	127.94	401	pc	51,303.94
183	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	1,070.00	3	pc	3,210.00
184	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	395.88	60	pc	23,752.80
185	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	400.00	180	pc	72,000.00
186	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	200.00	1,030	pc	206,000.00
187	Voriconazole 200mg lyophilized	4,699.00	264	pc	1,240,536.00

	powder for solution for IV infusion, 30mLVial				
Expected delivery timeframe after receipt of a Call-Off.			**Please refer to the Terms and Conditions**		
Remarks			*Indicate here any other appropriate information as may be necessary.*		
MARIA BERNADETTE P. IDJAO, MMPA ***SIGNATURE OVER PRINTED NAME***		***Chief*** ***POSITION***	***Property and Supply Division*** ***DEPARTMENT/DIVISION***		

Project Title:	**Supply and Delivery of Various Drugs and Medicines for Charity In-Patients and Resale- Ampules/Vials for CY2024 (Framework Agreement)**
Delivery Site	**UP – PHILIPPINE GENERAL HOSPITAL** Pharmacy Department Taft Avenue, Manila
Expected delivery timeframe after receipt of a Call-Off.	Delivery should be done within seven (7) days commencing on the third calendar day of notification through confirmed fax that the approved Call-Off is already available for pick-up.
Remarks	Suppliers are advised to maintain revolving stocks.

I hereby commit to deliver the required quality and quantities upon receipt of the Call-Off as indicated above.

_____
Name of Company

_____
Signature over Printed Name of Authorized Representative

_____
Date

Section VII. Technical Specifications

Notes for Preparing the Technical Specifications

A set of precise and clear specifications is a prerequisite for Bidders to respond realistically and competitively to the requirements of the Procuring Entity without qualifying their Bids. In the context of Competitive Bidding, the specifications (*e.g.* production/delivery schedule, manpower requirements, and after-sales service/parts, descriptions of the lots or items) must be prepared to permit the widest possible competition and, at the same time, present a clear statement of the required standards of workmanship, materials, and performance of the goods and services to be procured. Only if this is done will the objectives of transparency, equity, efficiency, fairness, and economy in procurement be realized, responsiveness of bids be ensured, and the subsequent task of bid evaluation and post-qualification facilitated. The specifications should require that all items, materials and accessories to be included or incorporated in the goods be new, unused, and of the most recent or current models, and that they include or incorporate all recent improvements in design and materials unless otherwise provided in the Contract.

Samples of specifications from previous similar procurements are useful in this respect. The use of metric units is encouraged. Depending on the complexity of the goods and the repetitiveness of the type of procurement, it may be advantageous to standardize the General Technical Specifications and incorporate them in a separate subsection. The General Technical Specifications should cover all classes of workmanship, materials, and equipment commonly involved in manufacturing similar goods. Deletions or addenda should then adapt the General Technical Specifications to the particular procurement.

Care must be taken in drafting specifications to ensure that they are not restrictive. In the specification of standards for equipment, materials, and workmanship, recognized Philippine and international standards should be used as much as possible. Where other particular standards are used, whether national standards or other standards, the specifications should state that equipment, materials, and workmanship that meet other authoritative standards, and which ensure at least a substantially equal quality than the standards mentioned, will also be acceptable. The following clause may be inserted in the Special Conditions of Contract or the Technical Specifications.

Sample Clause: Equivalency of Standards and Codes

Wherever reference is made in the Technical Specifications to specific standards and codes to be met by the goods and materials to be furnished or tested, the provisions of the latest edition or revision of the relevant standards and codes shall apply, unless otherwise expressly stated in the Contract. Where such standards and codes are national or relate to a particular country or region, other authoritative standards that ensure substantial equivalence to the standards and codes specified will be acceptable.

Reference to brand name and catalogue number should be avoided as far as possible; where unavoidable they should always be followed by the words "*or at least equivalent*." References to brand names cannot be used when the funding source is the GOP.

Where appropriate, drawings, including site plans as required, may be furnished by the Procuring Entity with the Bidding Documents. Similarly, the Supplier may be requested to
during contract execution.

Bidders are also required, as part of the technical specifications, to complete their statement of compliance demonstrating how the items comply with the specification.

[Use this form for Framework Agreement:]

Technical Specifications

IMPORTANT REMINDERS: *Bidders must state here either "Comply" or "Not Comply" against each of the individual parameters of each Specification stating the corresponding performance parameter of the medical and dental equipment as well as assistive devices offered.* ***Statements of "Comply" or "Not Comply" must be supported by evidence in a Bidders Bid and cross-referenced to that evidence.***

Evidence shall be in the form of manufacturer's un-amended sales literature*,* ***unconditional statements of specification and compliance issued by the manufacturer****,* ***samples****, independent test data, brochures, manuals, etc., as appropriate, which will provide substantial information of the goods or product/s to be supplied.*

A statement that is not supported by evidence or is subsequently found to be contradicted by the evidence presented will render the Bid under evaluation liable for rejection. *A statement either in the Bidder's statement of compliance or the supporting evidence that is found to be false either during Bid evaluation, post-qualification or the execution of the Contract may be regarded as fraudulent and render the Bidder or supplier liable for prosecution subject to the applicable laws and issuances.*

DIRECTION: Indicate either "Comply" or "Not Comply" under the *Statement of Compliance* column **and the appropriate attachment as reference document**.

TECHNICAL SPECIFICATIONS			
Item / Service	***Maximum Quantity***	***Technical Specifications / Scope of Work***	***Statement of Compliance***
1	680	Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)	
2	6,250	Aciclovir 25mg/mL, 10mL vial (IV infusion)	
3	2,373	Albumin Human 20%, 50mL bottle (IV, IV infusion)	
4	1,398	Adenosine 3 mg/mL, 2 mL vial (IV)	
5	14,447	Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)	
6	19,345	Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)	
7	742	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL	

		ampul (IV)	
8	6,704	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	
9	820	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	
10	820	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	
11	32,200	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	
12	10,970	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	
13	13,550	Ampicillin sodium 250mg vial (IM, IV)	
14	15,395	Ampicillin sodium 500mg vial (IM, IV)	
15	2	Asparaginase lyophilized powder, 10,000 IU vial (IV)	
16	8,748	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	
17	12,700	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	
18	5,550	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	
19	1,280	Aztreonam 1g powder for injection (IV, IV Infusion)	
20	243	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	
21	2	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	
22	10	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	
23	7,985	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	
24	5,680	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local infiltration)	

25	2,660	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	
26	1,670	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	
27	36,160	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	
28	600	Carbachol Intraocular Solution: 0.01%, 1.5 mL vial	
29	3,735	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	
30	17	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	
31	29,580	Cefazolin sodium 1gm vial (IM, IV)	
32	2,739	Cefepime Hydrochloride 1gm vial (IM, IV)	
33	1,790	Cefepime Hydrochloride 2gms vial (IM, IV)	
34	2,890	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	
35	26,705	Cefoxitin sodium 1gm vial (IM, IV)	
36	44,943	Ceftazidime pentahydrate 1gm vial (IM, IV)	
37	60,480	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	
38	12,613	Cefuroxime sodium 750mg vial (IM, IV)	
39	8,040	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	
40	12	Cisplatin 1mg/mL, 50mL vial (IV)	
41	6,120	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	
42	30,000	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	
43	3	Clonidine hydrocloride 150mcg/mL, 1mL ampule (IV)	
44	5,040	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	

45	12	Cytarabine 100 mg/mL solution for injection, 1 mL	
46	12	Cytarabine 100 mg/mL solution for injection, 5 mL	
47	8	Dantrolene Sodium 20 mg (with mannitol 3g)/vial (for reconstitution with 60 mL sterile water for injection) (IV) (With Compassionate Special Permit)	
48	1,620	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	
49	25,495	Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV)	
50	35,450	Dexamethasone sodium phoshate 5mg/mL, 1mL ampule (IM, IV)	
51	842	Dexmedetomidine 200mcg/2mL (100mcg/mL) single-dose glass vial	
52	1,010	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	
53	1,107	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	
54	11,495	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	
55	5,051	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	
56	2,845	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	
57	12	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	
58	35,393	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	
59	21,337	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	
60	5,300	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	
61	74,760	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	
62	632	Epoetin alfa (recombinant human erythropoetin) 10,000 IU/mL, pre-filled syringe (IV, SC)	

63	8,577	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	
64	485	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	
65	75	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	
66	3,418	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	
67	4,700	Ertapenem sodium 1gm powder vial (IM/IV)	
68	2,118	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	
69	3,970	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	
70	49,605	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	
71	2,560	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC)	
72	9,192	Fluconazole 2mg/mL, 100mL vial (IV infusion)	
73	266	Flumazenil 100 micrograms/mL, 5 mL ampul (slow IV, IV infusion)	
74	124	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	
75	600	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul (IV)	
76	6	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	
77	214	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	
78	84,820	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	
79	15	Ganciclovir sodium 500 mg vial (IV infusion)	

80	5	Gemcitabine Hydrochloride 1gm vial (IV infusion)	
81	5	Gemcitabine Hydrochloride 200mg vial (IV infusion)	
82	11,280	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	
83	38,638	Glucose (dextrose) 50%, 50mL vial (IV)	
84	9,165	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	
85	2	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	
86	2	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	
87	1,820	Haloperidol 5 mg/mL, 1 mL ampul (IM)	
88	6,344	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	
89	4,610	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	
90	35	Human recombinant tissue type plasminogen activator (alteplase) 50 mg powder for I.V. infusion	
91	778	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	
92	28,060	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	
93	10,960	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	
94	11,620	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	
95	3	Ifosfamide powder, 2gms vial (IV infusion)	
96	15	Insulin Glargine 100 IU/mL, 10 mL Vial	
97	2,151	Insulin, regular(recombinant DNA human) 100 IU/mL, 10mL vial (SC,	

		IV/IM)	
98	1,662	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	
99	1,984	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	
100	2,334	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	
101	3,299	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	
102	499	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV infusion)	
103	307	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	
104	61,400	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	
105	41	Leuproreline (as acetate) powder, 3.75mg single dose with syringe (IM, SC)	
106	8,665	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	
107	9,529	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	
108	15,250	Lidocaine Hydrochloride 2% (20 mg/mL), 2 mL ampul/vial (IM/IV)	
109	53,223	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	
110	2,725	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	
111	4,750	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	
112	164	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	
113	11,476	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	

114	37,590	Meropenem trihydrate 1g powder vial (IV)	
115	26,520	Meropenem trihydrate 500mg powder vial (IV)	
116	1,405	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	
117	685	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	
118	25	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	
119	168	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	
120	185	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	
121	1,570	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	
122	21,773	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	
123	18,375	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	
124	18,670	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	
125	5,080	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	
126	1,045	Milrinone 10mg/ml, 10ml ampule (IV)	
127	6,375	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	
128	3,235	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	

129	1,345	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	
130	19,735	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	
131	1,330	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	
132	39,653	Nicardipine Hydrochloride 1mg/mL, 10mL ampule (IV)	
133	3,360	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	
134	65,555	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	
135	20,640	Norepinephrine bitartrate 2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injection	
136	3,890	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	
137	81,570	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	
138	13,565	Ondansetron 2mg/mL, 2mL ampule (IM, IV)	
139	13,625	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	
140	28,925	Oxacillin sodium 500mg vial (IM, IV)	
141	3	Oxaliplatin 50mg vial powder (IV Infusion)	
142	29,780	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	
143	318,508	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	
144	8,360	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	
145	9,508	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	
146	748	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	

147	8,200	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	
148	2,815	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	
149	1,805	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	
150	1,981	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	
151	1,630	Phenytoin sodium 50mg/mL, 2mL ampule (IV)	
152	11,628	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	
153	26,895	Piperacillin + Tazobactam (as sodium salt) 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)	
154	46,445	Piperacillin + Tazobactam (as sodium salt) 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)	
155	26,614	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	
156	11,770	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	
157	29,730	Propofol 10mg/mL, 20mL ampule/vial (IV)	
158	1,326	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	
159	5,963	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	
160	140	Remdesivir 100mg vial lyophilized powder for injection for IV Infusion or 100mg/20ml solution for IV infusion (With Compassionate Special Permit)	
161	2,000	Remifentanil 1mg lyophilized	

		powder vial (IV Infusion) (With PDEA Permit)	
162	5,334	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	
163	2,640	Ropivacaine Hydrochloride 10mg/mL, 10mL ampule (IV)	
164	2,006	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	
165	24,646	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	
166	12,651	Sodium Chloride 2.5mEq/mL, 20mL vial	
167	20	Somatostatin 250mcg ampule/vial (IV, IV infusion)	
168	330	Somatostatin 3mg ampule/vial (IV, IV infusion)	
169	35	Streptokinase powder, 1,500,000 IU vial (IV infusion)	
170	8	Streptomycin sulfate 1 g vial (IM)	
171	3,150	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	
172	1,344	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	
173	849	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	
174	1	Tinzaparin (as sodium) 10,000 anti-Xa IU/mL, 0.45 mL pre-filled syringe (SC)	
175	5	Tocilizumab 400mg/ 20ml vial concentrate solution for IV Infusion	
176	23,108	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	
177	3,823	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	
178	65,740	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	
179	60	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	

180	16,573	Vancomycin Hydrochloride 500mg vial (IV)	
181	1,783	Vasopressin 20 IU/mL (IM, IV)	
182	401	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	
183	3	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	
184	60	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	
185	180	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	
186	1,030	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	
187	264	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	

Terms and Conditions:

1. Indicate the **brand and packing of the item/s** offered
2. The brand offered must be **at least five (5) years commercially available in the market from date of opening of bids.** Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).
3. **Submit the following documents, submission should be per product, with tab and per item number. Two (2) copies for the Valid Certificate of Product Registration and Certificate of Analysis (COA).**

   3.1. Memorandum of Agreement (MOA) and Certificate of exclusive/authorized distributorship between the manufacturer and distributor.

   Distributors/suppliers must have certification from their principals that they are the exclusive distributor of the drug products authorized to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distributorship agreement.

   3.2. **Valid Certificate of Product Registration (CPR)** issued by the Food and Drug Administration (FDA).

   - The name of the respective distributor should appear on the submitted CPR of the drug.

   Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.

   3.3. **Certificate of Analysis (COA)** for the products offered (batch to be delivered if awarded) duly issued by an FDA accredited laboratory (local) and should contain information indicated in monograph of the drug. Sample analyzed must not be expired during the time of bidding. The result of assay submitted must be in the specific brand and should be in the exact dosage formulation of the drug being bidded. In cases where local laboratories are unavailable to perform drug assays, assays done abroad is accepted. The local COA is preferred and given more weight in the evaluation and awarding process.

3.4. **A notarized certificate** that it is the innovator drug (if applicable).
3.5. **Certificate of Good Manufacturing Process (CGMP).**
3.6. **Valid License to Operate (LTO).**
3.7. **A notarized certificate that the offered brand has not been subject to product complaint/product recall** for the past three (3) years.
3.8. **Certificate of Acceptance** from at least three (3) major hospitals issued within the year and should be supported with Sales Invoice (*for new item/brand offered only).*
3.9. **A notarized certificate** that there are sufficient stocks for the offered item/s for one (1) year.

4. All the deliveries conform to the latest Philippine Food and Drug Administration (FDA) Administrative Order **governing the generic labeling and packaging requirements.**
   4.1. **For all tablets and capsules**
      4.1.1. **All tablets/capsules should be in foil or blister pack. A picture of the blister pack (front and back) should be submitted.**
      4.1.2. Each individual flap in the tablet or capsule blister pack should be labeled with the generic name and brand.
      4.1.3. Dosage form and strength of the Active Pharmaceutical Ingredients (API) should appear on each unit or every 2 units for products with multiple APIs.
      4.1.4. Name of drug, lot or batch number and expiry date must appear on every standard blister pack/foil strip and on the container or inner packing. However, if the product is not restricted for dispensing in quantities less than the standard blister pack or foil strip, the batch or lot number and expiry date should appear on each unit.
      4.1.5. Inner label must be the same as the outer label.
      4.1.6. A complete drug literature/product insert must accompany the product.
5. The following must be complied with specific for **cytotoxic injectable drugs.**
   For Inhalation Anaesthetics
      5.1.1. Submit certification from the bidder that inhalation bottle must be with safety sealed cap, airtight and capable to dispense directly from bottle the possibility of ambient air coming into contact with agent to prevent contamination and spillage
      5.1.2. Submit certification from the bidder that product container or anesthetic agent is shatterproof and transparent for visual check of content. Container material must ensure stability of the agent to prevent degradation, must not be easy to break.
      5.1.3. Winning bidder for Sevoflurane shall provide at least thirtyfive (35) vaporizers on loan and in good working conditions until the validity of the contract.
   5.2. For cytotoxic Injectable Drugs
      5.2.1. For cytotoxic injectable drugs, winning bidders are required to *provide Material Safety Data Sheet (MSDS) and to submit Drug Profile* to the Pharmacy Department per company under the first Purchase Order.
      5.2.2. Winning bidders for cytotoxic injectable drugs are required to **provide at least three (3) spill kits** per company under the first Purchase Order.
      5.2.3. For Paclitaxel, a special IV set bmust be provided per unit of the drug.
6. The brand offered on all antibiotics must have stability that is equivalent to that of the innovator product or better.
7. **New brands offered** shall be subject to further evaluation and shall require the following:
   7.1. Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals

7.2. Justification from end-user/s to validate the acceptance of the good/s offered (to be facilitated by PGH-PSD).

8. For the supply and delivery of awarded drugs and medicines.

8.1. Delivery of the goods is required as stated in the request of the end-user, commencing on the 3rd working day of notification through confirmed fax/email that the approved Call-off/ Notice to Supplier (NTS) is already available for pick up.

8.2. Delivery schedule (whichever is applicable):

8.2.1. within seven (7) calendar days;

8.2.2. as may be called for;

8.2.3. staggered delivery within three (3) months

* 50% of the total quantity within seven (7) calendar days and 25% each for the succeeding months

Note: The end-user has the right to adjust the quantity to be delivered depending on the actual need of the hospital

8.3. Deliveries should not be less than eighteen (18) months from the time of delivery. Deliveries expiring within twelve (12) months should be guaranteed for replacement if not consumed within six (6) months. A credit memo shall be submiited or effect replacement of fresher stocks within five (5) working days upon receipt of Notice to Supplier (NTS) for pull-out.

8.4. Delivery of goods **with product complaint shall be put on hold** until receipt of the final decision of the PGH management whether to proceed with the acceptance or to cancel/return the items

8.5. Delivered **items found to be non-formulary at any given time shall be returned** to the company and a credit memo shall be issued.

8.6. Stocks delivered are subject to random sampling for testing as to quality and conformity to label. Testing fee at supplier's expense.

8.7. Stocks with lot #/batch different from the submitted Certificate of Analysis (COA) will be subjected to testing as to quality and conformity to label. Testing fee at supplier's expense.

8.8. All items that had been pulled out for various reasons, a credit memo shall be issued by the Contractor within one (1) month, otherwise, a debit memo shall be processed by UP Manila - PGH and the amount will be deducted from any amount due to Supplier.

8.9. It is understood that the Supplier is legally responsible to deliver all issued **CALL-OFF/s** (Purchase Order) and **failure to deliver the first Call-Off as scheduled shall mean automatic cancellation of the Call-Off and Notice to Execute Framework Agreement (NEFA).** Purchase from other source for whatever means shall be effected immediately to provide the requirements of the hospital. Penalty to the defaulting contractor shall be charged accordingly.

9. Failure to comply with the submission of the required documents shall be ground for post-disqualification in accordance with RA9184.

10. Compliance with RA 9184 and other applicable laws.

I hereby certify to comply and deliver all the above requirements:

_____
Name of Company

_____
Signature over Printed Name of Authorized Representative

_____
Date

Section VIII. Checklist of Technical and Financial Documents

Notes on the Checklist of Technical and Financial Documents

The prescribed documents in the checklist are mandatory to be submitted in the Bid, but shall be subject to the following:

a. GPPB Resolution No. 09-2020 on the efficient procurement measures during a State of Calamity or other similar issuances that shall allow the use of alternate documents in lieu of the mandated requirements; or

b. Any subsequent GPPB issuances adjusting the documentary requirements after the effectivity of the adoption of the PBDs.

The BAC shall be checking the submitted documents of each Bidder against this checklist to ascertain if they are all present, using a non-discretionary "pass/fail" criterion pursuant to Section 30 of the 2016 revised IRR of RA No. 9184.

Checklist of Technical and Financial Documents

I. TECHNICAL COMPONENT ENVELOPE

Class "A" Documents

Legal Documents

☐ (a) Valid PhilGEPS Registration Certificate (Platinum Membership) (all pages) **in accordance with Section 8.5.2 of the IRR**;
Or

☐ **(b)** Registration certificate from Securities and Exchange Commission (SEC), Department of Trade and Industry (DTI) for sole proprietorship, or Cooperative Development Authority (CDA) for cooperatives or its equivalent document, **and**

☐ (c) Mayor's or Business permit issued by the city or municipality where the principal place of business of the prospective bidder is located, or the equivalent document for Exclusive Economic Zones or Areas; a**nd**

☐ (d) Tax clearance per E.O. No. 398, s. 2005, as finally reviewed and approved by the Bureau of Internal Revenue (BIR)

☐ (e) Notarized UP Questionnaire

Technical Documents

☐ (f) Statement of the prospective bidder of all its ongoing government and private contracts, including contracts awarded but not yet started, if any, whether similar or not similar in nature and complexity to the contract to be bid; **and**

☐ (g) Statement of the bidder's Single Largest Completed Contract (SLCC) similar to the contract to be bid, except under conditions provided for in Sections 23.4.1.3 and 23.4.2.4 of the 2016 revised IRR of RA No. 9184, within the relevant period as provided in the Bidding Documents; **and**

☐ **(h)** Original copy of Bid Security. If in the form of a Surety Bond, submit also a certification issued by the Insurance Commission **or** Original copy of Notarized Bid Securing Declaration; **and**

☐ (i) Conformity with the Technical Specifications, which may include production/delivery schedule, manpower requirements, and/or after-sales/parts, if applicable; **and**

☐ **(j)** Original duly signed Omnibus Sworn Statement (OSS) **and** if applicable, Original Notarized Secretary's Certificate in case of a corporation, partnership, or cooperative; or Original Special Power of Attorney of all members of the joint venture giving full power and authority to its officer to sign the OSS and do acts to represent the Bidder.

Financial Documents

☐ (k) The Supplier's audited financial statements, showing, among others, the Supplier's total and current assets and liabilities, stamped "received" by the BIR or its duly accredited and authorized institutions, for the preceding calendar year which should not be earlier than two (2) years from the date of bid submission;

☐ **(l)** The prospective bidder's computation of Net Financial Contracting Capacity (NFCC);

or

A committed Line of Credit from a Universal or Commercial Bank in lieu of its NFCC computation.

Class "B" Documents

☐ (m) If applicable, a duly signed joint venture agreement (JVA) in case the joint venture is already in existence;

or

duly notarized statements from all the potential joint venture partners stating that they will enter into and abide by the provisions of the JVA in the instance that the bid is successful.

II. FINANCIAL COMPONENT ENVELOPE

☐ (a) Original of duly signed and accomplished Financial Bid Form;

☐ (b) Original of duly signed and accomplished Price Schedule (s); **and**

☐ (c) Original of duly signed and accomplished Price Schedule (s) "Annex A"

Other documentary requirements under RA No. 9184 (as applicable)

☐ (a) *[For foreign bidders claiming by reason of their country's extension of reciprocal rights to Filipinos]* Certification from the relevant government office of their country stating that Filipinos are allowed to participate in government procurement activities for the same item or product.

☐ (b) Certification from the DTI if the Bidder claims preference as a Domestic Bidder or Domestic Entity.

Bid Form

Date: _____
Project Reference No.: _____

THE BIDS AND AWARDS COMMITTEE 1
UPM – Philippine General Hospital
Taft Avenue, Manila

Gentlemen and/or Ladies:

Having examined the Philippine Bidding Documents (PBDs) including the Supplemental or Bid Bulletin Numbers *[insert numbers]*, the receipt of which is hereby duly acknowledged, we, the undersigned, offer to *Supply and Deliver Medical Oxygen and Other Gases* in conformity with the said PBDs for the sum of *[total Bid amount in words and figures]* or the total calculated bid price, as evaluated and corrected for computational errors, and other bid modifications in accordance with the Price Schedules attached herewith and made part of this Bid. The total bid price includes the cost of all taxes, such as, but not limited to: *[specify the applicable taxes, e.g. (i) value added tax (VAT), (ii) income tax, (iii) local taxes, and (iv) other fiscal levies and duties]*, which are itemized herein or in the Price Schedules,

If our Bid is accepted, we undertake:

a. to deliver the goods in accordance with the delivery schedule specified in the Schedule of Requirements of the Philippine Bidding Documents (PBDs);

b. to provide a performance security in the form, amounts, and within the times prescribed in the PBDs;

c. to abide by the Bid Validity Period specified in the PBDs and it shall remain binding upon us at any time before the expiration of that period.

Until a formal Contract is prepared and executed, this Bid, together with your written acceptance thereof and your Notice of Award, shall be binding upon us.

We understand that you are not bound to accept the Lowest Calculated Bid or any Bid you may receive.

We certify/confirm that we comply with the eligibility requirements pursuant to the PBDs.

The undersigned is authorized to submit the bid on behalf of *[name of the bidder]* as evidenced by the attached *[state the written authority]*.

We acknowledge that **failure to sign each and every page of this Bid Form**, including the attached Schedule of Prices, shall be a ground for the rejection of our bid.

Name: _____

Legal capacity: _____

Signature: _____

Duly authorized to sign the Bid for and behalf of: _____

Date: _____

Price Schedule for Goods Offered from Abroad

[shall be submitted with the Bid if bidder is offering goods from Abroad]

For Goods Offered from Abroad

Name of Bidder: _____ Project Reference No. _____

Page ___ of ___

1	2	3	4	5	6	7	8	9	10
Item	Description	Country of origin	Brand Name	Quantity	Unit price CIF port of entry (specify port) or CIP named place (specify border point or place of destination)	Total CIF or CIP price per item (col. 5 x 6)	Unit Price Delivered Duty Unpaid (DDU)	Unit price Delivered Duty Paid (DDP)	Total Price delivered DDP (col 5 x 9)

Name: _____

Legal Capacity: _____

Signature: _____

Duly authorized to sign the Bid for and behalf of: _____

Price Schedule for Goods Offered from Within the Philippines

[shall be submitted with the Bid if bidder is offering goods from within the Philippines]

For Goods Offered from Within the Philippines

Name of Bidder _____ Project Ref No.: _____

Page ___of___

1	2	3	4	5	6	7	8	9	10	11
Item	Description	Country of origin	Brand Name	Quantity	Unit price EXW per item	Transportation and all other costs incidental to delivery, per item	Sales and other taxes payable if Contract is awarded, per item	Cost of Incidental Services, if applicable, per item	Total Price, per unit (col 6+7+8+9)	Total Price delivered Final Destination (col 10) x (col 5)

Name: _____

Legal Capacity: _____

Signature: _____

Duly authorized to sign the Bid for and behalf of: _____

Contract Agreement

THIS AGREEMENT made the _____ day of _____ 20_____ between [name of PROCURING ENTITY] of the Philippines (hereinafter called "the Entity") of the one part and [name of Supplier] of [city and country of Supplier] (hereinafter called "the Supplier") of the other part;

WHEREAS, the Entity invited Bids for certain goods and ancillary services, particularly [brief description of goods and services] and has accepted a Bid by the Supplier for the supply of those goods and services in the sum of *[contract price in words and figures in specified currency]* (hereinafter called "the Contract Price").

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

1. In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract referred to.

2. The following documents as required by the 2016 revised Implementing Rules and Regulations of Republic Act No. 9184 shall be deemed to form and be read and construed as integral part of this Agreement, *viz.*:

   i. Philippine Bidding Documents (PBDs);
      i. Schedule of Requirements;
      ii. Technical Specifications;
      iii. General and Special Conditions of Contract; and
      iv. Supplemental or Bid Bulletins, if any

   ii. Winning bidder's bid, including the Eligibility requirements, Technical and Financial Proposals, and all other documents or statements submitted;

      Bid form, including all the documents/statements contained in the Bidder's bidding envelopes, as annexes, and all other documents submitted (*e.g.*, Bidder's response to request for clarifications on the bid), including corrections to the bid, if any, resulting from the Procuring Entity's bid evaluation;

   iii. Performance Security;

   iv. Notice of Award of Contract; and the Bidder's conforme thereto; and

   v. Other contract documents that may be required by existing laws and/or the Procuring Entity concerned in the PBDs. **Winning bidder agrees that additional contract documents or information prescribed by the GPPB that are subsequently required for submission after the contract execution, such as the Notice to Proceed, Variation Orders, and Warranty Security, shall likewise form part of the Contract.**

3. In consideration for the sum of *[totalcontract price in words and figures]* or such other sums as may be ascertained, *[Named of the bidder]* agrees to *[state the object of the contract]* in accordance with his/her/its Bid.

4. The *[Name of the procuring entity]* agrees to pay the above-mentioned sum in accordance with the terms of the Bidding.

IN WITNESS whereof the parties hereto have caused this Agreement to be executed in accordance with the laws of the Republic of the Philippines on the day and year first above written.

[Insert Name and Signature] *[Insert Signatory's Legal Capacity]* *for:* *[Insert Procuring Entity]*	*[Insert Name and Signature]* *[Insert Signatory's Legal Capacity]* *for:* *[Insert Name of Supplier]*

Acknowledgment

[Format shall be based on the latest Rules on Notarial Practice]

FRAMEWORK AGREEMENT

KNOW ALL MEN BY THESE PRESENTS:

This Agreement entered into by and between:

The **UNIVERSITY OF THE PHILIPPINES,** the national university of the Philippines, a public and secular institution of higher learning, created by virtue of Act No. 1870, as amended and reorganized and operating by virtue of Republic Act No. 9500, through its constituent university, University of the Philippines Manila through the **PHILIPPINE GENERAL HOSPITAL (PGH)**, with address at the Office of the Director, Ground Floor, Philippine General Hospital Complex, Taft Avenue, Manila, represented in this Agreement by the PGH Director, **DR. GERARDO D. LEGASPI**, hereinafter referred to as the "**PROCURING ENTITY";**

- and -

_____., a *(sole proprietorship/ domestic corporation/ partnership)* duly organized and existing under and by virtue of the laws of the Philippines with principal business address at _____, Philippines represented by its _____, **Mr/Ms. _____,** hereinafter referred to as the "**SUPPLIER**".

WITNESSETH THAT:

WHEREAS, the PROCURING ENTITY decided to use Framework Agreement on its procurement project: _____ under project reference no. _____ with Contract Price amounting to _____ _____ (Php_____) with NEFA No. _____, herein attached as ***Annex "A".***

WHEREAS, this Agreement is for the option to purchase of goods determined to be necessary and desirable to address and satisfy the needs of the PROCURING ENTITY but by its nature, use or characteristic, the quantity and/or exact time of need cannot be accurately pre-determined;

WHEREAS, the PROCURING ENTITY has the option to purchase the items provided in the Framework Agreement List, attached and made an integral part of this Agreement as provided in Article I, on a date and time to be determined in the Call-Off to be issued for such purpose by the PROCURING ENTITY; and

WHEREAS, the SUPPLIER which passed the eligibility screening conducted by the PROCURING ENTITY, shall maintain and update the eligibility requirements during period of this Agreement and shall honor all obligations under this Framework Agreement.

NOW, THEREFORE, the parties hereby agree as follows:

Article I
GENERAL CONSIDERATIONS

1. This Framework Agreement is an option contract. The PROCURING ENTITY is given the option to either purchase the identified items in the Framework Agreement or not to purchase at all. The discretion to exercise the option falls solely with the PROCURING ENTITY. The SUPPLIER may not require or demand for the latter to purchase the items in the Framework Agreement List.

2. In this Framework Agreement, words and expressions shall have the same meanings as are respectively assigned to them in the Conditions of Contract which is attached thereto and made and integral part thereof.

3. The following documents shall be deemed to form and be read and construed as part of this Agreement:
    a. the Supplier's Bid, including the Technical and Financial Proposals, and all other documents/ statements submitted (*e.g.*, bidder's response to clarifications on the bid), including corrections to the bid resulting from the Procuring Entity's bid evaluation;
    b. the Framework Agreement List and the Technical Specifications;
    c. the General Conditions of Contract;
    d. the Special Conditions of Contract;
    e. the Performance Security or Performance Securing Declaration;
    f. the Procuring Entity's Notice to Execute Framework Agreement;
    g. Mini-Competition, when necessary; and
    h. Call-Offs.

Article II
DURATION

The term of this Agreement shall be from **_____** to **_____,** unless sooner revoked by both parties.

Article III
CONSIDERATION

For the consideration of **One Peso (Php 1.00)**, the PROCURING ENTITY has the option to purchase any or all of the items in the Framework Agreement List through the issuance of Call-off and the SUPPLIER commits to deliver the goods and perform the services, subject to the conditions of the Call-off.

Article IV
PERFECTION OF PROCUREMENT CONTRACT

The Framework Agreement being an option contract, a procurement contract is perfected only when the PROCURING ENTITY exercises the option to procure any item from the Framework Agreement List through the issuance of a Call-off.

Article V
OBLIGATION TO ANSWER A CALL-OFF

Once the PROCURING ENTITY issues a Call-off, the SUPPLIER is bound to deliver the goods or perform the services identified at the time and date specified in the Call-off.

Failure on the part of the SUPPLIER to deliver goods or perform the services shall warrant forfeiture of performance security or performance securing declaration and imposition of liquidated damages as provided for in the Guidelines on use of Framework Agreement by all Procuring Entities without prejudice to all other applicable sanctions.

Article VI
TERMS AND CONDITIONS

The terms and conditions of this Framework Agreement shall be governed by Guidelines on the Use of Framework Agreement by all Procuring Entity and all relevant issuance of the GPPB.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed in accordance with the laws of the Republic of the Philippines, on the day and year first above written

UNIVERSITY OF THE PHILIPPINES
Manila – Philippine General Hospital
Procuring Entity

_____
Supplier

By:

By:

GERARDO D. LEGASPI, M.D
Director

_____
(Position/Designation of the Authorized Signatory)

Signed in the presence of:

MARIA MARGARITA LAT - LUNA
Deputy Director for Fiscal Services

_____
(Witness)

Republic of the Philippines)
) s.s.

ACKNOWLEDGMENT

SUBSCRIBED AND SWORN TO before me this _____, affiants exhibiting to me their respective Competent Evidence of Identity, as indicated below:

Name	**Government Issued ID No.** (Passport, Driver's License, GSIS ID Card, COMELEC Voter's ID or PRC License)	**Date / Place Issued**
DR. GERARDO D. LEGASPI	_____	_____
_____	_____	_____

known to me and to me known to be the same persons who executed the foregoing instrument and acknowledged to me that the same is free and voluntary act and deed, and of the institutions they respectively represent.

WITNESS MY HAND AND NOTARIAL SEAL on the date and place first mentioned.

NOTARY PUBLIC

Doc. No.: _____;
Page No.: _____;
Book No.: _____;
Series of 2023.

Omnibus Sworn Statement

REPUBLIC OF THE PHILIPPINES)
CITY/MUNICIPALITY OF _____) S.S.

A F F I D A V I T

I, [Name of Affiant], of legal age, [Civil Status], [Nationality], and residing at [Address of Affiant], after having been duly sworn in accordance with law, do hereby depose and state that:

1. *[Select one, delete the other:]*

   [If a sole proprietorship:] I am the sole proprietor or authorized representative of [Name of Bidder] with office address at [address of Bidder];

   [If a partnership, corporation, cooperative, or joint venture:] I am the duly authorized and designated representative of [Name of Bidder] with office address at [address of Bidder];

2. *[Select one, delete the other:]*

   [If a sole proprietorship:] As the owner and sole proprietor, or authorized representative of [Name of Bidder], I have full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for [Name of the Project] of the [Name of the Procuring Entity], as shown in the attached duly notarized Special Power of Attorney;

   [If a partnership, corporation, cooperative, or joint venture:] I am granted full power and authority to do, execute and perform any and all acts necessary to participate, submit the bid, and to sign and execute the ensuing contract for [Name of the Project] of the [Name of the Procuring Entity], as shown in the attached [state title of attached document showing proof of authorization (e.g., duly notarized Secretary's Certificate, Board/Partnership Resolution, or Special Power of Attorney, whichever is applicable;)];

3. [Name of Bidder] is not "blacklisted" or barred from bidding by the Government of the Philippines or any of its agencies, offices, corporations, or Local Government Units, foreign government/foreign or international financing institution whose blacklisting rules have been recognized by the Government Procurement Policy Board, **by itself or by relation, membership, association, affiliation, or controlling interest with another blacklisted person or entity as defined and provided for in the Uniform Guidelines on Blacklisting;**

4. Each of the documents submitted in satisfaction of the bidding requirements is an authentic copy of the original, complete, and all statements and information provided therein are true and correct;

5. [Name of Bidder] is authorizing the Head of the Procuring Entity or its duly authorized

representative(s) to verify all the documents submitted;

6. *[Select one, delete the rest:]*

   [If a sole proprietorship:] The owner or sole proprietor is not related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

   [If a partnership or cooperative:] None of the officers and members of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

   [If a corporation or joint venture:] None of the officers, directors, and controlling stockholders of *[Name of Bidder]* is related to the Head of the Procuring Entity, members of the Bids and Awards Committee (BAC), the Technical Working Group, and the BAC Secretariat, the head of the Project Management Office or the end-user unit, and the project consultants by consanguinity or affinity up to the third civil degree;

7. *[Name of Bidder]* complies with existing labor laws and standards; and

8. *[Name of Bidder]* is aware of and has undertaken the responsibilities as a Bidder in compliance with the Philippine Bidding Documents, which includes:

   a. Carefully examining all of the Bidding Documents;
   b. Acknowledging all conditions, local or otherwise, affecting the implementation of the Contract;
   c. Making an estimate of the facilities available and needed for the contract to be bid, if any; and
   d. Inquiring or securing Supplemental/Bid Bulletin(s) issued for the *[Name of the Project]*.

9. *[Name of Bidder]* did not give or pay directly or indirectly, any commission, amount, fee, or any form of consideration, pecuniary or otherwise, to any person or official, personnel or representative of the government in relation to any procurement project or activity.

10. **In case advance payment was made or given, failure to perform or deliver any of the obligations and undertakings in the contract shall be sufficient grounds to constitute criminal liability for Swindling (Estafa) or the commission of fraud with unfaithfulness or abuse of confidence through misappropriating or converting any payment received by a person or entity under an obligation involving the duty to deliver certain goods or services, to the prejudice of the public and the government of the Philippines pursuant to Article 315 of Act No. 3815 s. 1930, as amended, or the Revised Penal Code.**

IN WITNESS WHEREOF, I have hereunto set my hand this __ day of ___, 20__ at _____, Philippines.

[Insert NAME OF BIDDER OR ITS AUTHORIZED REPRESENTATIVE]
[Insert signatory's legal capacity]
Affiant

[Jurat]
[Format shall be based on the latest Rules on Notarial Practice]

Bank Guarantee Form for Advance Payment

TO: **UP- PHILIPPINE GENERAL HOSPITAL**
Taft Avenue, Manila

Name of Contract: _____
_____
_____
under Project Reference No. _____

Gentlemen and/or Ladies:

In accordance with the payment provision included in the Special Conditions of Contract, which amends Clause **Error! Reference source not found.** of the General Conditions of Contract to provide for advance payment, *[name and address of Supplier]* (hereinafter called the "Supplier") shall deposit with the PROCURING ENTITY a bank guarantee to guarantee its proper and faithful performance under the said Clause of the Contract in an amount of *[amount of guarantee in figures and words]*.

We, the *[bank or financial institution]*, as instructed by the Supplier, agree unconditionally and irrevocably to guarantee as primary obligator and not as surety merely, the payment to the PROCURING ENTITY on its first demand without whatsoever right of objection on our part and without its first claim to the Supplier, in the amount not exceeding *[amount of guarantee in figures and words]*.

We further agree that no change or addition to or other modification of the terms of the Contract to be performed thereunder or of any of the Contract documents which may be made between the PROCURING ENTITY and the Supplier, shall in any way release us from any liability under this guarantee, and we hereby waive notice of any such change, addition, or modification.

This guarantee shall remain valid and in full effect from the date of the advance payment received by the Supplier under the Contract until *[date]*.

Yours truly,

Signature and seal of the Guarantors

_____
[name of bank or financial institution]

_____
[address]

_____
[date]

Bid Securing Declaration Form

REPUBLIC OF THE PHILIPPINES)
CITY OF _____) S.S.

x----------x

BID SECURING DECLARATION
Project Reference No.:_____

To: **UPM-PHILIPPINE GENERAL HOSPITAL**
Taft Avenue, Manila

I/We, the undersigned, declare that:

1. I/We understand that, according to your conditions, bids must be supported by a Bid Security, which may be in the form of a Bid Securing Declaration.

2. I/We accept that: (a) I/we will be automatically disqualified from bidding for any procurement contract with any procuring entity for a period of two (2) years upon receipt of your Blacklisting Order; and, (b) I/we will pay the applicable fine provided under Section 6 of the Guidelines on the Use of Bid Securing Declaration, within fifteen (15) days from receipt of the written demand by the procuring entity for the commission of acts resulting to the enforcement of the bid securing declaration under Sections 23.1(b), 34.2, 40.1 and 69.1, except 69.1(f),of the IRR of RA No. 9184; without prejudice to other legal action the government may undertake.

3. I/We understand that this Bid Securing Declaration shall cease to be valid on the following circumstances:

   a. Upon expiration of the bid validity period, or any extension thereof pursuant to your request;
   b. I am/we are declared ineligible or post-disqualified upon receipt of your notice to such effect, and (i) I/we failed to timely file a request for reconsideration or (ii) I/we filed a waiver to avail of said right; and
   c. I am/we are declared the bidder with the Lowest Calculated Responsive Bid, and I/we have furnished the performance security and signed the Contract.

IN WITNESS WHEREOF, I/We have hereunto set my/our hand/s this ____ day of *[month] [year]* at *[place of execution]*.

[Insert NAME OF BIDDER OR ITS AUTHORIZED REPRESENTATIVE]
[Insert signatory's legal capacity]
Affiant

[Jurat]
[Format shall be based on the latest Rules on Notarial Practice]

Performance Securing Declaration (Revised)

[if used as an alternative performance security but it is not required to be submitted with the Bid, as it shall be submitted within ten (10) days after receiving the Notice of Award/Notice to Execute Framework Agreement]

REPUBLIC OF THE PHILIPPINES)
CITY OF _____) S.S.

PERFORMANCE SECURING DECLARATION
Project Reference No.:_____

To: **UPM-PHILIPPINE GENERAL HOSPITAL**
Taft Avenue, Manila

I/We, the undersigned, declare that:

1. I/We understand that, according to your conditions, to guarantee the faithful performance by the supplier/distributor/manufacturer/contractor/consultant of its obligations under the Contract, I/we shall submit a Performance Securing Declaration within a maximum period of ten (10) calendar days from the receipt of the Notice of Award prior to the signing of the Contract.

2. I/We accept that: I/we will be automatically disqualified from bidding for any procurement contract with any procuring entity for a period of one (1) year for the first offense, or two (2) years **for the second offense**, upon receipt of your Blacklisting Order if I/We have violated my/our obligations under the Contract;

3. I/We understand that this Performance Securing Declaration shall cease to be valid upon:

    a. issuance by the Procuring Entity of the Certificate of Final Acceptance, subject to the following conditions:
        i. Procuring Entity has no claims filed against the contract awardee;
        ii. It has no claims for labor and materials filed against the contractor; and
        iii. Other terms of the contract; or

    b. replacement by the winning bidder of the submitted PSD with a performance security in any of the prescribed forms under Section 39.2 of the 2016 revised IRR of RA No. 9184 as required by the end-user.

IN WITNESS WHEREOF, I/We have hereunto set my/our hand/s this ____ day of [month] [year] at [place of execution].

[Insert NAME OF BIDDER OR ITS AUTHORIZED REPRESENTATIVE]
[Insert signatory's legal capacity]
Affiant

[Jurat]
[Format shall be based on the latest Rules on Notarial Practice]

NET FINANCIAL CONTRACTING CAPACITY (NFCC)

Project Reference No.: _____

ABC: _____

A. Summary of the Applicant Supplier's/Distributor's/Manufacturer's assets and liabilities on the basis of the **Audited Financial Statements**, submitted to the Bureau of Internal Revenue (BIR).

		Year 2022
1.	Total Assets	
2.	Current Assets	
3.	Total Liabilities	
4.	Current Liabilities	
5.	Net Worth (1-3)	
6.	Net Working Capital (2-4)	

B. The Net Financial Contracting Capacity (NFCC) using the following formula, must be equal to the ABC to be bid:

NFCC = [(current assets – current liabilities) (15)] minus value of all outstanding or uncompleted portions of the projects under ongoing contracts, including awarded contracts yet to be started coinciding with the contract to be bid.

NFCC Computation

DETAILS	**AMOUNT**
Current Assets	
Minus	
Current Liabilities	
Difference of Current Assets and Current Liabilities	
Multiplied by	
K	15
Total (Product)	
Minus	
Total amount of the Value of Outstanding Contracts	
Total NFCC Computation	

_____ _____

(Signature over Printed Name of Authorized Representative) *(Signatory's Legal Capacity)*

Duly authorized to sign Bid for and on behalf of _____

Standard Form Number: SF-GOOD-17
Revised on: May 24, 2004

Philippine General Hospital

Name of Project: _____

_____

Location of Project: **Dietary Department, PGH**

Joint Venture Agreement

KNOWN ALL BY THESE PRESENTS:

That this JOINT VENTURE AGREEMENT is entered into By and Between _____, of legal age, _____, owner/proprietor of _____
(civil status)
and a resident of _____.

-and-

_____, of legal age, _____,
(civil status)
owner/proprietor of _____ a resident of _____

_____.

That both parties agree to join together their manpower, equipment, and what is need to facilitate the Joint Venture to participate in the Eligibility, Bidding and Undertaking of the here-under stated project to be conducted by the University of the Philippines Manila/Philippine General Hospital.

NAME OF PROJECT CONTRACT AMOUNT

That both parties agree to jointly and severely liable for the entire assignment.

That both parties agree that _____ and/or _____ shall be the Official Representative of the Joint Venture, and is granted full power and authority to do, execute and perform any and all acts necessary and /or to represent the Joint Venture in the bidding as fully and effectively and the Joint Venture may do and if personally present with full power of substitution and revocation.

That this Venture Agreement shall remain in effect only for the above stated Projects until terminated by both parties.

Done this ___ day of _____, in the year of the Lord _____

_____
(Name of Company)

_____
(Address of the Company)
_____
(Telephone & Fax of the Company)
_____
(Website Address of the Company)
_____
(e-Mail Address of the Company)

(Letterhead of the Company/Agency)

_____
(Date of Issuance)

Letter of Acceptance

This is to certify that _____ has satisfactorily delivered
(Name of Bidder)

_____
(Item Description)

under P.O. No/s. _____ with Sales Invoice No. _____ and accepted on _____. Said company has no more pending obligation with us regarding their delivery/ies.

_____
(Signature over Printed Name)

_____
(Position)

_____
(Company Name)

Note: This is a sample template only

University of the Philippines
Diliman, Quezon City

Questionnaire for Prospective Bidders

(additional requirement for eligibility)

1. Have you ever participated in any bidding in the University of the Philippines System?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Amount of Project	Duration Start/End (Dates)	Status (On-going/ Completed)

2. Has your company ever been suspended or blacklisted by the University of the Philippines System?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Reason for suspension/ blacklisting	Status (On-going/ Completed)

3. Has your company ever been suspended or blacklisted by any government agency or private company?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

Name of government agency/ company	Name of the Project	Reason for suspension/ blacklisting	Status (On-going/ Completed)

4. Has there ever been any project of your company in the University of the Philippines that was terminated by Administration?

YES	NO	NA

If YES, fill up the table below. Use additional pages if necessary.

Constituent University/UP Campus	Name of the Project	Reason for suspension/ blacklisting	Status (On-going/ Completed)

5. Do you certify that all the documents submitted by your Company and personnel are authentic?

YES	NO

6. Is there any pending investigation and/or case filed against your Company or your personnel in any court or any similar institution in relation to any government contracts awarded to your company? In relation to practice of profession of any of your personnel?

YES	NO

If YES, fill up the table below. Use additional pages if necessary.

For Company

Case Filed	Where Filed	Date Filed	Status (On-going/ Completed)	Remarks

For Personnel

Case Filed	Where Filed	Date Filed	Status (On-going/ Completed)	Remarks

I hereby certify that all statements and information provided herein are complete, true and correct.

Name & Signature of Bidder : _____
Authorized Representative : _____
Official Designation : _____
Company : _____
Date : _____

ACKNOWLEDGEMENT

SUBSCRIBED AND SWORN TO before me this _____ day of _____, 20__, affiant exhibited to me his/her Community Tax Certificate No. _____ issued on _____ at _____, Philippines.

Notary Public
Until 31 December 20___
PTR No.: _____
Issued at: _____
Issued on: _____
TIN: _____

Standard Form Number: SF-GOOD-13a
University of the Philippines /Philippine General Hospital

Project Reference No. _____
Name of Project: _____
_____
- Location of Project: **Property and Supply Division**
UP-Philippine General Hospital

Statement of All On-Going Government and Private Contracts

Including Contracts Awarded But Not Yet Started

BusinessName:_____
BusinessAddress_____

Name of Contract/ Project Cost	a. Owner's Name b. Address c. Telephone Nos.	Nature of Work	Bidder's Role		a. Date Awarded b. Date Started c. Date of Completion	% of accomplishment		Value of Outstanding Works/Undelivered Portion
			Description	%		Planned	Actual	
Government								
Private								

Total Cost

Note: This statement shall be supported with:
1. Notice of Award and/or Contract
2. Notice to Proceed

Submitted by : _____
(Printed Name & Signature)
Designation : _____
Date : _____

"Annex A"

Project Reference No. _____
Name of Project: **SUPPLY AND DELIVERY OF**
Location of Project: **Property and Supply Division, UP-Philippine General Hospital**

Statement of the Single Largest Completed Contract

Business Name: _____
Business Address: _____

Name of Contract	**a. Owner's Name b. Address c. Telephone Nos.**	**Nature of Work**	**Bidder's Role**		**a. Amount at Award b. Amount at Completion c. Duration**	**a. Date Awarded b. Contract Effectivity c. Date Completed**
			Description	**%**		
Government						
Private						

Note: This statement shall be supported with:
1. Contract
2. Certificate of Completion
3. Certification of Acceptance

Submitted by : _____
(Printed Name & Signature)

Designation : _____
Date :_____

PRICE SCHEDULE

Project Reference Nos.: BAC1-2023-11-0100A and BAC1-2023-11-0101A Supply and Delivery of Various Drugs and Medicines for Charity In-Patients and Resale – Ampules/Vials for CY2024 - Framework Agreement
under Public Bidding

Opening of Bid: 02 February 2024, Friday, 9:30 AM
BAC Conference Room, UP-PGH, Taft Avenue, Manila

AGENCY's REQUIREMENTS						BID PROPOSAL				Remarks
Item No.	Item Description	Qty	UOM	Unit Cost	Total Cost	Bidder's Specifications	Brand	Unit Cost	Total Cost	
1	Acetylcysteine 200mg/mL, 25mL vial/bottle (IV infusion)	680	pc	1,500.00	1,020,000.00					
2	Aciclovir 25mg/mL, 10mL vial (IV infusion)	6,250	pc	219.49	1,371,812.50					
3	Albumin Human 20%, 50mL bottle (IV, IV infusion)	2,373	pc	2,387.00	5,664,351.00					
4	Adenosine 3 mg/mL, 2 mL vial (IV)	1,398	pc	286.89	401,072.22					
5	Amikacin sulfate 125mg/mL , 2mL ampule/vial (IM, IV)	14,447	pc	74.00	1,069,078.00					
6	Amikacin sulfate 250mg/mL , 2mL ampule/vial (IM, IV)	19,345	pc	97.88	1,893,488.60					
7	Aminophylline (theophylline ethylenediamine) 25 mg/mL, 10 mL ampul (IV)	742	pc	38.00	28,196.00					
8	Amiodarone hydrochloride 50 mg/mL, 3 mL ampul (IV)	6,704	pc	495.00	3,318,480.00					
9	Amphotericin B non lipid complex 50mg lyophilized powder, vial (IV infusion)	820	pc	3,300.00	2,706,000.00					
10	Amphotericin B Lipid Complex (as cholesteryl complex, colloidal dispersion) 50 mg vial (IV infusion)	820	pc	10,972.00	8,997,040.00					

11	Ampicillin + Sulbactam 1000 mg ampicillin + 500 mg sulbactam (IM, IV) (as sodium salt) per vial	32,200	pc	230.00	7,406,000.00					
12	Ampicillin + Sulbactam 500 mg ampicillin + 250 mg sulbactam (IM, IV) (as sodium salt) per vial	10,970	pc	245.00	2,687,650.00					
13	Ampicillin sodium 250mg vial (IM, IV)	13,550	pc	35.00	474,250.00					
14	Ampicillin sodium 500mg vial (IM, IV)	15,395	pc	55.00	846,725.00					
15	Asparaginase lyophilized powder, 10,000 IU vial (IV)	2	pc	1,700.00	3,400.00					
16	Atracurium besilate 10mg/mL, 2.5mL ampule (IV)	8,748	pc	327.00	2,860,596.00					
17	Atropine sulfate 1mg/mL, 1 mL ampul (IM, IV, SC)	12,700	pc	115.00	1,460,500.00					
18	Azithromycin 500 mg powder, vial (IV infusion) (as base*/as dihydrate)	5,550	pc	605.00	3,357,750.00					
19	Aztreonam 1g powder for injection (IV, IV Infusion)	1,280	pc	1,290.00	1,651,200.00					
20	Beractant 25 mg/ml suspension, 8mL Intratracheal administration vial	243	pc	15,776.53	3,833,696.79					
21	Beractant 25 mg/mL suspension, 4 mL Intratracheal administration vial	2	pc	12,178.00	24,356.00					
22	Bleomycin sulfate powder, 15 IU ampul/vial (IM,IV)	10	pc	2,300.00	23,000.00					
23	Bupivacaine Hydrochloride 0.5% 4 mL ampul (spinal) with 8% dextrose	7,985	pc	565.00	4,511,525.00					
24	Bupivacaine Hydrochloride 0.5%, 10mL ampul/vial (local	5,680	pc	327.00	1,857,360.00					

	infiltration)									
25	Butorphanol tartrate 2 mg/mL, 1 mL ampul/vial (IM, IV)	2,660	pc	689.00	1,832,740.00					
26	Calcium folinate (leucovorin Ca) 10mg/mL, 5mL ampule/vial (IM, IV)	1,670	pc	180.00	300,600.00					
27	Calcium Gluconate 10%, 10 mL ampul/vial (IV)	36,160	pc	119.00	4,303,040.00					
28	Carbachol Intraocular Solution: 0.01%, 1.5 mL vial	600	pc	750.00	450,000.00					
29	Carbetocin 100 mcg/mL, 1 mL ampule/vial, solution for Injection (IV)	3,735	pc	1,320.00	4,930,200.00					
30	Carboprost 250 mcg/mL solution for injection, 1 mL ampule/vial	17	pc	500.00	8,500.00					
31	Cefazolin sodium 1gm vial (IM, IV)	29,580	pc	280.00	8,282,400.00					
32	Cefepime Hydrochloride 1gm vial (IM, IV)	2,739	pc	350.00	958,650.00					
33	Cefepime Hydrochloride 2gms vial (IM, IV)	1,790	pc	398.45	713,225.50					
34	Cefotaxime sodium 500 mg vial + 2 mL diluent (IM, IV)	2,890	pc	698.00	2,017,220.00					
35	Cefoxitin sodium 1gm vial (IM, IV)	26,705	pc	935.00	24,969,175.00					
36	Ceftazidime pentahydrate 1gm vial (IM, IV)	44,943	pc	200.00	8,988,600.00					
37	Ceftriaxone disodium/sodium 1gm vial + 10mL diluent (IV)	60,480	pc	365.00	22,075,200.00					
38	Cefuroxime sodium 750mg vial (IM, IV)	12,613	pc	88.00	1,109,944.00					
39	Ciprofloxacin lactate 2mg/mL, 100mL vial (IV infusion)	8,040	pc	350.00	2,814,000.00					

40	Cisplatin 1mg/mL, 50mL vial (IV)	12	pc	450.00	5,400.00					
41	Clindamycin phosphate 150mg/mL, 2mL ampule/vial (IM, IV)	6,120	pc	198.00	1,211,760.00					
42	Clindamycin phosphate 150mg/mL, 4mL ampule (IM, IV)	30,000	pc	370.00	11,100,000.00					
43	Clonidine hydrocloride 150mcg/mL, 1mL ampule (IV)	3	pc	110.00	330.00					
44	Colistin 2,000,000 IU lyophilized powder for injection (IV infusion)	5,040	pc	2,244.00	11,309,760.00					
45	Cytarabine 100 mg/mL solution for injection, 1 mL	12	pc	129.46	1,553.52					
46	Cytarabine 100 mg/mL solution for injection, 5 mL	12	pc	355.36	4,264.32					
47	Dantrolene Sodium 20 mg (with mannitol 3g)/vial (for reconstitution with 60 mL sterile water for injection) (IV) (With Compassionate Special Permit)	8	pc	18,099.00	144,792.00					
48	Deferoxamine mesilate powder, 500 mg vial (IM, IV infusion, SC)	1,620	pc	183.32	296,978.40					
49	Dexamethasone sodium phoshate 4 mg/mL, 2 mL ampul/vial (IM, IV)	25,495	pc	33.43	852,297.85					
50	Dexamethasone sodium phoshate 5mg/mL, 1mL ampule (IM, IV)	35,450	pc	79.78	2,828,201.00					
51	Dexmedetomidine 200mcg/2mL (100mcg/mL) single-dose glass vial	842	pc	2,105.30	1,772,662.60					

52	Diazepam 5 mg/mL, 2 mL ampul (IM, IV) (With PDEA Permit)	1,010	pc	138.48	139,864.80					
53	Digoxin 250 micrograms/mL, 2 mL ampul (IM, IV)	1,107	pc	200.00	221,400.00					
54	Diphenhydramine Hydrochloride 50 mg/mL, 1 mL ampul (IM, IV)	11,495	pc	98.00	1,126,510.00					
55	Dobutamine Hydrochloride 50mg/mL, 5ml ampule (IV infusion)	5,051	pc	238.00	1,202,138.00					
56	Dopamine Hydrochloride 40mg/mL 5mL vial/ampule (IV)	2,845	pc	147.45	419,495.25					
57	Doxorubicin Hydrochloride powder, 50mg vial or 2mg/mL, 25mL vial (IV)	12	pc	510.00	6,120.00					
58	Enoxaparin sodium 100mg/mL, 0.4mL pre-filled syringe (SC)	35,393	pc	550.00	19,466,150.00					
59	Enoxaparin sodium 100mg/mL, 0.6mL pre-filled syringe (SC)	21,337	pc	500.00	10,668,500.00					
60	Ephedrine sulfate 50 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	5,300	pc	88.84	470,852.00					
61	Epinephrine Hydrochloride 1mg/mL, 1mL ampule (IV, IM, SC)	74,760	pc	32.00	2,392,320.00					
62	Epoetin alfa (recombinant human erythropoetin) 10,000 IU/mL, pre-filled syringe (IV, SC)	632	pc	1,498.00	946,736.00					
63	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC)	8,577	pc	530.00	4,545,810.00					

64	Epoetin alfa (recombinant human erythropoietin) 2000 IU/0.5 mL, pre-filled syringe (IV, SC)	485	pc	312.50	151,562.50					
65	Epoetin Beta (recombinant erythropoietin) 2000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	75	pc	407.67	30,575.25					
66	Epoetin Beta (recombinant erythropoietin) 5000 IU/0.3 mL, pre-filled syringe with needle (IV, SC)	3,418	pc	1,278.98	4,371,553.64					
67	Ertapenem sodium 1gm powder vial (IM/IV)	4,700	pc	2,144.00	10,076,800.00					
68	Esmolol Hydrochloride 10mg/mL, 10mL vial (IV)	2,118	pc	487.00	1,031,466.00					
69	Famotidine 20 mg powder/lyophilized powder for injection, ampule/vial (IV)	3,970	pc	497.00	1,973,090.00					
70	Fentanyl citrate 50mcg/mL, 2mL amp (IV) (With PDEA Permit)	49,605	pc	58.00	2,877,090.00					
71	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC)	2,560	pc	2,578.00	6,599,680.00					
72	Fluconazole 2mg/mL, 100mL vial (IV infusion)	9,192	pc	500.00	4,596,000.00					
73	Flumazenil 100 micrograms/mL, 5 mL ampul (slow IV, IV infusion)	266	pc	829.50	220,647.00					
74	Fluphenazine (as decanoate) 25mg/mL, 1mL ampule (IM)	124	pc	78.72	9,761.28					
75	Fluorescein (as sodium salt) 10% (100mg/mL), 5 mL ampul	600	pc	575.00	345,000.00					

	(IV)									
76	Fluorouracil 50 mg/mL, 10 mL ampul/vial (IV, IV infusion)	6	pc	74.80	448.80					
77	Fondaparinux sodium 2.5 mg/0.5 mL solution (IV, SC)	214	pc	1,447.04	309,666.56					
78	Furosemide 10 mg/mL, 2 mL ampul (IM, IV)	84,820	pc	15.00	1,272,300.00					
79	Ganciclovir sodium 500 mg vial (IV infusion)	15	pc	1,828.47	27,427.05					
80	Gemcitabine Hydrochloride 1gm vial (IV infusion)	5	pc	1,550.00	7,750.00					
81	Gemcitabine Hydrochloride 200mg vial (IV infusion)	5	pc	450.00	2,250.00					
82	Gentamicin sulfate 40mg/mL, 2mL ampule/vial (IM, IV)	11,280	pc	29.45	332,196.00					
83	Glucose (dextrose) 50%, 50mL vial (IV)	38,638	pc	78.00	3,013,764.00					
84	Glyceryl trinitrate (nitroglycerin) 1mg/mL, 10mL ampule (IV infusion)	9,165	pc	436.80	4,003,272.00					
85	Goserelin acetate 10.8mg depot solution pre-filled syringe (SC)	2	pc	15,767.24	31,534.48					
86	Goserelin acetate 3.6mg depot solution, pre-filled syringe (SC)	2	pc	4,613.06	9,226.12					
87	Haloperidol 5 mg/mL, 1 mL ampul (IM)	1,820	pc	731.00	1,330,420.00					
88	Heparin sodium unfractionated 1,000 iu/mL, 5mL vial (IV infusion, SC) (bovine origin)	6,344	pc	288.00	1,827,072.00					
89	Heparin sodium unfractionated 5000 IU/mL, 5 mL vial (IV infusion, SC) (bovine origin)	4,610	pc	500.00	2,305,000.00					
90	Human recombinant tissue type plasminogen activator	35	pc	32,062.83	1,122,199.05					

	(alteplase) 50 mg powder for I.V. infusion									
91	Hydralazine Hydrochloride 20 mg/mL, 1 mL ampul (IM, IV)	778	pc	54.00	42,012.00					
92	Hydrocortisone sodium succinate 50mg/mL, 2mL vial or 100mg powder vial (IV)	28,060	pc	150.00	4,209,000.00					
93	Hydrocortisone sodium succinate 125 mg/mL, 2 mL vial (IV) or 250 mg powder vial (IV)	10,960	pc	370.00	4,055,200.00					
94	Hyoscine-n-butylbromide 20mg/mL, 1mL ampule (IM, IV, SC)	11,620	pc	57.00	662,340.00					
95	Ifosfamide powder, 2gms vial (IV infusion)	3	pc	2,025.00	6,075.00					
96	Insulin Glargine 100 IU/mL, 10 mL Vial	15	pc	929.46	13,941.90					
97	Insulin, regular(recombinant DNA human) 100 IU/mL, 10mL vial (SC, IV/IM)	2,151	pc	580.00	1,247,580.00					
98	Insulin, Biphasic Isophane Human 70/30 (recombinant DNA) 70% isophane suspension + 30% soluble insulin in 100 IU/mL, 10 mL vial (SC)	1,662	pc	580.00	963,960.00					
99	Isophane Insulin Human (recombinant DNA) 100 IU/mL, 10 mL vial (SC)	1,984	pc	398.00	789,632.00					
100	Isosorbide dinitrate 1mg/ml, 10mL ampule (IV)	2,334	pc	544.01	1,269,719.34					
101	Iron sucrose 20mg/mL, 5mL ampule (IV, IV infusion)	3,299	pc	220.00	725,780.00					
102	Isoxsuprine hydrochloride 5 mg/mL, 2 mL ampul (IM, IV	499	pc	216.00	107,784.00					

	infusion)									
103	Ketamine hydrochloride 50 mg/mL, 10 mL vial (IM, IV) (With PDEA Permit)	307	pc	1,729.00	530,803.00					
104	Ketorolac tromethamol 30 mg/mL, 1 mL ampul (IM, IV)	61,400	pc	45.00	2,763,000.00					
105	Leuproreline (as acetate) powder, 3.75mg single dose with syringe (IM, SC)	41	pc	4,160.00	170,560.00					
106	Levetiracetam 500 mg/5 mL (100 mg/mL) concentrate solution for IV infusion, 5 mL vial	8,665	pc	1,725.00	14,947,125.00					
107	Levofloxacin 5 mg/mL solution for IV infusion, 100mL vial	9,529	pc	935.00	8,909,615.00					
108	Lidocaine Hydrochloride 2% (20 mg/mL), 2 mL ampul/vial (IM/IV)	15,250	pc	56.00	854,000.00					
109	Lidocaine Hydrochloride 2%, 5mL ampule/vial (IM/IV)	53,223	pc	35.00	1,862,805.00					
110	Lidocaine Hydrochloride 2%, 50mL ampule/vial (IM, IV)	2,725	pc	50.00	136,250.00					
111	Lidocaine Hydrochloride 2%, 1.8 mL carpule (with epinephrine) (local infiltration)	4,750	pc	36.00	171,000.00					
112	Linezolid 2 mg/mL (600 mg/300 mL), solution for infusion (IV)	164	pc	2,669.94	437,870.16					
113	Magnesium sulfate heptahydrate 250mg/mL, 20mL vial (IV)	11,476	pc	50.00	573,800.00					
114	Meropenem trihydrate 1g powder vial (IV)	37,590	pc	650.00	24,433,500.00					
115	Meropenem trihydrate 500mg	26,520	pc	500.00	13,260,000.00					

	powder vial (IV)									
116	Mesna (sodium-2mercapto ethanesulphonate) 100mg/mL, 4mL ampule (IV)	1,405	pc	145.00	203,725.00					
117	Methotrexate 25 mg/mL, 2 mL ampul/vial (IM, IV, Intrathecal) (as base)	685	pc	200.00	137,000.00					
118	Methotrexate sodium 100mg/mL, 10mL vial (IM, IV, Intrathecal) (preservative free)	25	pc	5,000.00	125,000.00					
119	Methylergometrine (methylergonovine) (as hydrogen maleate or maleate) 200 micrograms/mL, 1 mL ampul (IM, IV)	168	pc	89.98	15,116.64					
120	Methylprednisolone 40 mg in single dose vial, solution for injection (IV, IM) (as sodium succinate)	185	pc	320.00	59,200.00					
121	Methylprednisolone lyophilized powder, 500 mg vial (IM, IV) (as sodium succinate)	1,570	pc	4,099.31	6,435,916.70					
122	Metoclopramide 5mg/mL, 2mL ampule (As Base and As Hydrochloride) (IM/IV)	21,773	pc	14.73	320,716.29					
123	Metronidazole 5 mg/mL, 100 mL vial (IV infusion)	18,375	pc	79.86	1,467,427.50					
124	Midazolam 1mg/mL, 5mL ampule or 5mg/mL, 1mL ampule (IM, IV) (With PDEA Permit)	18,670	pc	102.00	1,904,340.00					
125	Midazolam 5mg/mL, 3mL ampule (IM, IV) (With PDEA Permit)	5,080	pc	104.89	532,841.20					

126	Milrinone 10mg/ml, 10ml ampule (IV)	1,045	pc	1,689.10	1,765,109.50					
127	Morphine Sulfate 10 mg/mL, 1 mL ampul (IM, IV, SC) or 16 mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	6,375	pc	78.45	500,118.75					
128	Nalbuphine Hydrochloride 10 mg/mL, 1 mL ampul (IM, IV, SC) (With PDEA Permit)	3,235	pc	189.88	614,261.80					
129	Naloxone hydrochloride 400 micrograms/mL, 1 mL ampul (IM, IV, SC)	1,345	pc	413.00	555,485.00					
130	Neostigmine 500 mcg/mL solution for injection (IM/IV/SC), 1 mL ampule	19,735	pc	118.00	2,328,730.00					
131	Nicardipine Hydrochloride 1mg/mL, 2mL ampule (IV)	1,330	pc	95.00	126,350.00					
132	Nicardipine Hydrochloride 1mg/mL, 10mL ampule (IV)	39,653	pc	385.00	15,266,405.00					
133	Norepinephrine bitartrate 1mg/mL, 2mL ampule (IV infusion)	3,360	pc	175.00	588,000.00					
134	Norepinephrine bitartrate 1mg/mL, 4mL ampule (IV infusion)	65,555	pc	450.00	29,499,750.00					
135	Norepinephrine bitartrate 2 mg /mL, 4 mL ampule (8 mg/4 mL) solution for injection	20,640	pc	1,650.00	34,056,000.00					
136	Octreotide acetate 100 micrograms/mL ampul (IV infusion)	3,890	pc	600.00	2,334,000.00					
137	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	81,570	pc	240.00	19,576,800.00					
138	Ondansetron 2mg/mL, 2mL	13,565	pc	212.78	2,886,360.70					

	ampule (IM, IV)									
139	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	13,625	pc	360.00	4,905,000.00					
140	Oxacillin sodium 500mg vial (IM, IV)	28,925	pc	90.00	2,603,250.00					
141	Oxaliplatin 50mg vial powder (IV Infusion)	3	pc	1,160.00	3,480.00					
142	Oxytocin (synthetic) 10 IU/mL, 1 mL ampul (IM, IV)	29,780	pc	295.00	8,785,100.00					
143	Paracetamol 150mg/mL, 2mL ampule solution for injection (IM, IV)	318,508	pc	12.00	3,822,096.00					
144	Paracetamol 10 mg/mL, 50 mL vial solution for infusion (IV)	8,360	pc	248.88	2,080,636.80					
145	Paracetamol 10 mg/mL, 100 mL vial solution for infusion (IV)	9,508	pc	238.00	2,262,904.00					
146	Penicillin G benzathine (benzathine benzylpenicillin) 1,200,000 units vial (MR) (IM)	748	pc	150.00	112,200.00					
147	Penicillin G crystalline (benzylpenicillin) sodium 1,000,000 units vial (IM, IV)	8,200	pc	18.50	151,700.00					
148	Penicillin G crystalline (benzylpenicillin) sodium 5,000,000 units vial (IM, IV)	2,815	pc	28.50	80,227.50					
149	Pethidine (meperidine) (as hydrochloride) 50 mg/mL, 2 mL ampul (IM, IV, SC) (With PDEA Permit)	1,805	pc	492.00	888,060.00					
150	Phenylephrine hydrochloride 10mg/1mL vial (With Compassionate Special Permit) (IV/IV Infusion)	1,981	pc	554.40	1,098,266.40					
151	Phenytoin sodium 50mg/mL,	1,630	pc	670.00	1,092,100.00					

	2mL ampule (IV)									
152	Phytomenadione (phytonadione, vitamin K1) 10mg/mL, 1mL ampul (IM, IV, SC) (as mixed micelle)	11,628	pc	45.89	533,608.92					
153	Piperacillin + Tazobactam (as sodium salt) 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)	26,895	pc	298.00	8,014,710.00					
154	Piperacillin + Tazobactam (as sodium salt) 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)	46,445	pc	450.00	20,900,250.00					
155	Polymyxin B sulfate 500,000 Units powder for solution for injection (Intrathecal/IM/IV), 5 mL vial	26,614	pc	3,992.00	106,243,088.00					
156	Potassium chloride 2meq/mL, 20mL vial (IV infusion)	11,770	pc	53.00	623,810.00					
157	Propofol 10mg/mL, 20mL ampule/vial (IV)	29,730	pc	445.00	13,229,850.00					
158	Protamine sulfate 10mg/mL, 5mL ampule (IV) (With Compassionate Special Permit)	1,326	pc	640.00	848,640.00					
159	Ranitidine hydrochloride 25 mg/mL, 2 mL ampul/vial (IM, IV, IV infusion)	5,963	pc	32.00	190,816.00					
160	Remdesivir 100mg vial lyophilized powder for injection for IV Infusion or 100mg/20ml solution for IV infusion (With Compassionate Special Permit)	140	pc	969.11	135,675.40					
161	Remifentanil 1mg lyophilized powder vial (IV Infusion) (With	2,000	pc	1,649.00	3,298,000.00					

	PDEA Permit)									
162	Rocuronium bromide 10 mg/mL, 5 mL ampul/vial (IV)	5,334	pc	212.39	1,132,888.26					
163	Ropivacaine Hydrochloride 10mg/mL, 10mL ampule (IV)	2,640	pc	396.46	1,046,654.40					
164	Sodium Bicarbonate 1 mEq/mL, 20 mL ampul/vial (adult) (IV infusion)	2,006	pc	249.79	501,078.74					
165	Sodium bicarbonate 1mEq/mL, 50mL ampul/vial (adult) (IV infusion)	24,646	pc	147.44	3,633,806.24					
166	Sodium Chloride 2.5mEq/mL, 20mL vial	12,651	pc	65.00	822,315.00					
167	Somatostatin 250mcg ampule/vial (IV, IV infusion)	20	pc	754.95	15,099.00					
168	Somatostatin 3mg ampule/vial (IV, IV infusion)	330	pc	4,758.04	1,570,153.20					
169	Streptokinase powder, 1,500,000 IU vial (IV infusion)	35	pc	4,500.00	157,500.00					
170	Streptomycin sulfate 1 g vial (IM)	8	pc	28.00	224.00					
171	Sugammadex 100 mg/mL solution for injection (IV), 2 mL vial	3,150	pc	5,540.89	17,453,803.50					

172	Suxamethonium (succinylcholine) chloride 20 mg/mL, 10 mL vial (IV)	1,344	pc	698.00	938,112.00					
173	Terbutaline sulfate 500mcg/mL, 1mL ampule (IM, IV, SC)	849	pc	98.88	83,949.12					
174	Tinzaparin (as sodium) 10,000 anti-Xa IU/mL, 0.45 mL pre-filled syringe (SC)	1	pc	711.57	711.57					
175	Tocilizumab 400mg/ 20ml vial concentrate solution for IV Infusion	5	pc	25,480.00	127,400.00					
176	Tramadol Hydrochloride 50mg/mL, 1mL ampule (IM, IV, SC)	23,108	pc	34.80	804,158.40					
177	Tramadol Hydrochloride 50mg/mL, 2mL ampule (IM, IV, SC)	3,823	pc	60.00	229,380.00					
178	Tranexamic acid 100mg/mL, 5mL ampule (IM, IV)	65,740	pc	50.00	3,287,000.00					
179	Valproic Acid 500 mg/ 5mL IV infusion, 5 mL vial	60	pc	2,405.00	144,300.00					
180	Vancomycin Hydrochloride 500mg vial (IV)	16,573	pc	995.00	16,490,135.00					
181	Vasopressin 20 IU/mL (IM, IV)	1,783	pc	1,564.50	2,789,503.50					

182	Verapamil Hydrochloride 2.5 mg/mL, 2 mL ampul (IV)	401	pc	127.94	51,303.94					
183	Vinblastine sulfate 1 mg/mL, 10 mL vial (IV)	3	pc	1,070.00	3,210.00					
184	Vincristine sulfate 1 mg/mL, 1 mL vial (IV)	60	pc	395.88	23,752.80					
185	Vincristine sulfate 1 mg/mL, 2 mL vial (IV)	180	pc	400.00	72,000.00					
186	Vitamin B1 B6 B12 100 mg B1 + 100 mg B6 + 1 mg B12 per 3 mL ampul (IV)	1,030	pc	200.00	206,000.00					
187	Voriconazole 200mg lyophilized powder for solution for IV infusion, 30mLVial	264	pc	4,699.00	1,240,536.00					
Approved Budget for the Contract					**699,403,119.25**	**Total Bid Offer**				

Printed Name of the Company | *Date* | *Signature*

Business Address | *Contact No.* | *Printed Name and Designation*

e-Mail Address | *e-Mail Address*

Sample Diagram for Bid Packaging



Sealing and Marking of Envelopes

All folders / envelopes shall be marked in accordance with Section 20.4 of the Instruction to Bidders in the Bidding Documents, which shall contain the following:

- Name of the contract to be bid in **CAPITAL LETTERS**;
-

SUPPLY & DELIVERY OF VARIOUS DRUGS AND MEDICINES FOR CHARITY IN PATIENTS AND RESALE- AMPULES/VIALS FOR CY2024 (FRAMEWORK AGREEMENT)

- Name and address of the prospective bidder in **CAPITAL LETTERS**;

- Be addressed to the Procuring Entity's BAC in accordance with ITB Clause 1.1;

BIDS AND AWARDS COMMITTEE (BAC) 1
UP – PHILIPPINE GENERAL HOSPITAL
TAFT AVENUE, MANILA

- Bear the specific identification of this bidding process indicated in ITB Clause 1.2;

Project Reference No.: BAC1-2023-11-0100A & BAC1-2023-11-0101A

Bear a warning "**DO NOT OPEN BEFORE**…" the date and time for the opening of bids, in accordance with ITB Clause 18

The color of folder and envelope to be used is Violet


Republic of the Philippines
gppb
Government Procurement Policy Board